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resumo 
 
 
A doença de Machado-Joseph também conhecida como ataxia 
espinhocerebelosa tipo 3 (MJD/SCA3) é uma doença neurodegenerativa 
hereditária descrita pela primeira vez em emigrantes portugueses da região 
dos Açores. É a ataxia autossómica dominante mais comum e apresenta 
manifestações clínicas severas com um desfecho fatal. Esta doença é causada 
por uma expansão instável do trinucleótido CAG na região codificante do gene 
MJD1, que se traduz numa cadeia  com um número excessivo de glutaminas 
na ataxina-3. A ataxina-3 mutante adquire propriedades tóxicas e desencadeia 
uma patogénese complexa com manifestações heterogéneas.   
 
Apesar da expansão poliglutamínica na proteína ataxina-3 ser suficiente para 
induzir a patogénese da doença e do número de repetições se correlacionar 
inversamente com a idade de início dos sintomas, não permite explicar toda a 
diversidade na idade de iníco e nas manifestações clínicas. Há evidências de 
que a interação entre diferentes proteinas pode afectar quer a idade de ínicio 
dos sintomas quer a progressão da doença. 
Na procura de modificadores da neurodegeneração da DMJ estudos recentes 
sugerem que a  ataxina-2, uma proteína envolvida na ataxia espinocerebelosa 
do tipo 2 (SCA2) que interage com a proteína ligante da cadeia de poliadenina 
do RNA mensageiro (PABP) e poderá potenciar a neurodegeneração na DMJ. 
O objectivo principal deste trabalho foi investigar a interacção entre a ataxina-
2, PABP e a ataxina-3 na DMJ. 
Utilizando material humano (tecido cerebral e fibroblastos), animais 
trangénicos para a doença, um modelo lentiviral em roedor e ainda um modelo 
celular da doença, observámos que os níveis de ataxina-2 e PABP sofrem 
alterações na DMJ. A imunoreactividade para a ataxina-2 encontra-se 
aumentada no tecido humano dos doentes, o que também ocorreu também no 
murganos trangénicos. No modelo lentiviral observámos um recrutamento de 
ambas as proteínas para o núcleo da célula coincidente com a progressão da 
doença. 
O modelo celular revelou um feedback positivo entre os níveis de ataxina-2 e 
PABP, que poderá estar na base da sua capacidade de reduzir os níveis de 
ataxina-3 mutante na doença. Provando assim que os níveis das três proteínas 
parecem ser interdependentes, permanecendo a questão se esta interação 
ocorre de forma directa ou indirecta.  
Estes estudos sugerem que os níveis e consequente toxicidade de uma 
proteína poliglutamínica mutada pode ser modulada pela actividade normal de 
outra. Esta relação sinérgica pode ser crítica para a patogénese da doença e 
desta forma constituir um potencial alvo terapêutico. 
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abstract 
 
Machado-Joseph disease also known as Spinocerebellar ataxia type 3 
(MJD/SCA3) is a hereditary neurodegenerative disease first described among 
Portuguese immigrants from Azores. Is the most common autossomal domi-
nant spinocerebellar ataxia worldwide and it presents severe clinical features 
with a fatal outcome. This disease is caused by an unstable expansion of the 
trinucleotide CAG in the coding region of the MJD1 gene, the mutation is trans-
lated into an expanded polyglutamine tract in the protein ataxin-3. The mutant 
ataxin-3 acquires toxic properties and leads to a downstream of pathogenic 
mechanisms that make MJD a very heterogeneous disease. 
Although the polyglutamine expansion in ataxin-3 is sufficient for the pathogen-
esis of the disease and for the number of repeats is correlated inversely with 
the age of onset, clinical observations suggest that the polyQ expansion does 
not account for all the diversity in the age of onset and clinical manifestations. 
Interactions between different proteins may affect the age of onset as well as 
the disease progression.  
In a screen for modifiers of neurodegeneration in MJD, previous studies found 
ataxin-2, a protein involved in the spinocerebellar ataxia type 2 (SCA2) which 
interacts with poly (A)-binding protein (PABP) and may potentiate the neuro-
degeneration in MJD. The main goal of our research was to investigate the 
relation between ataxin-2, PABP and ataxin-3 in MJD.  
Recurring to human material (brain tissue and fibroblasts), transgenic mice for 
MJD, a lentiviral-based MJD mouse model and a cellular model of the disease, 
we observed that levels of ataxin-2 and PABP suffer alterations in MJD. The 
ataxin-2 immunoreactivity is increased in the human tissue of MJD patients, 
which also occurred in the transgenic rodents. In the lentiviral model we ob-
served both proteins’ recruitment into the nucleus with the progression of the 
disease.  
The cellular model revealed a positive feedback between ataxin-2 and PABP 
that may to be responsible for their capacity in reducing mutant ataxin-3 levels 
in the disease. Attesting that the levels of the three proteins seem to be inter-
dependent, remaining only the question whether this interaction occurs direct or 
indirectly.   
These studies indicate that the levels and the consequent toxicity of a polyglu-
tamine disease protein can be modulated by the normal activity of another. This 
synergicall relation may be critical for the pathogenesis of the disease and 
therefore be a potential therapeutic target. 
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(Student’s t-test). Three replicates of the protocol were performed. (C) Optical densitometry 
analysis. Significant increase in PABP levels was detected (relative to tubulin) in 
Atx3WT+Atx2 cells relatively to the Atx2WT cells. A similar occurrence was observed in the 
levels of PABP in Atx3MUT+Atx2 relatively to Atx3MUt cells. Each PABP lane was normalized 
according to the tubulin band. Tubulin was used as a loading control. Results were expressed 
as ratio PABP/ Tubulin (n=3 for each experimental set). Values are expressed as mean ± SEM. 
*P<0.05; ***P<0.001 (Student’s t-test).  .......................................................................................................... 66 
Figure 20. PABP overexpression decreases the levels of ataxin-3 expression and increases 
the levels of ataxin-2 expression. (A-C) Western blotting analysis of non-infected cells (NI, 
n=3), or cells infected with lentiviral vectors encoding, respectively: human wild-type ataxin-
3 (Atx3WT, n=3), human wild-type ataxin 3 and PABP (Atx3WT+PABP, n=3), human 
expanded ataxin-3 (Atx3MUT, n=3), human expanded ataxin-3 and PABP (Atx3MUT+PABP, 
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(tubulin band). Results were expressed as ratio PABP/tubulin (n=3 for each experimental 
set). Values are expressed as mean ± SEM. **P<0.01; **P<0.01 (Student’s t-test). (C) Optical 
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1.1. Diseases of unstable triplet repeat expansions 
 An important development in the understanding of the pathogenesis of a group of 
neurodegenerative diseases occurred more than 20 years ago, with the identification of a 
mutational mechanism that is behind their pathogenesis, the expansion of unstable 
nucleotide repeats (Koshy and Zoghbi, 1997; Gatchel and Zoghbi 2005). In the case of triplet 
repeat diseases, they are caused by an unstable expansion of a trinucleotide repeat (Gatchel 
and Zoghbi 2005). In normal conditions, there is a stable transmission of the number of 
repeats from the parents, but when there is a mutation involving excessive repetition of the 
triplet over a certain threshold it becomes unstable in the parental transmission, leading to 
variations of the number of repeats from one generation to the next. These intergenerational 
instability leads to an earlier onset and a more severe phenotype in successive generations of 
an affected family (Timchenco and Caskey, 1996; Tsuji, 1997; Koshy and Zoghbi, 1997). 
 These diseases are classified depending on the genetic context of the unstable repeat; it 
may occur an expansion of coding repeats (exons) or an expansion of non-coding repeats 
(5’UTR, 3’UTR or introns) (Fig.1). The expansion of non-coding repeats, leads to the 
alteration of gene expression, which reflects in either a loss of protein function or altered 
RNA function (Tsuji, 1997; Gatchel and Zoghbi, 2005). The other subclass of these disorders is 
caused by the expansion of an unstable Cytosine-Adenine-Guanine (CAG) trinucleotide repeat 
within the protein-encoding region, which translates into an abnormally long stretch of 
glutamine residues, conferring a toxic function to the protein unrelated to its normal function. 
These diseases are called polyglutamine diseases and are characterized by mutant proteins 
with expanded polyglutamine (polyQ) tracts (Tsuji, 1997; Ross and Poirer, 2004; Gatchel and 
Zoghbi, 2005; Riley and Orr, 2006). 
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Figure 1: Representation of the possible localization of triplet repeats for various diseases. 
(Adapted from Tsuji, 1997).  
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1.2. Polyglutamine diseases 
 The polyglutamine disorders are autosomal and are dominantly inherited (except SBMA 
(spinal bulbar muscular atrophy), an X-linked recessive disorder), representing the most 
common form of inherited neurodegenerative disease. The first polyglutamine disease to be 
discovered was SBMA in 1991 (La Spada and Keneth Fischbeck, 1991). They are caused by a 
polyglutamine (polyQ) expansion within their active coding unrelated proteins, including 
Huntington's disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), spinal bulbar 
muscular atrophy (SBMA), and the spinocerebellar ataxias (SCA1, 2, 3, 6, 7 and 17) (Table1) 
(Orr and Zoghbi, 2000).  
Table 1. Polyglutamine diseases 
*Main regions affected.  
 
Disease Disease Protein Normal subcellular 
localization 
Affected brain regions* 
Huntington’s disease (HD) Huntingtin (htt) Cytoplasmic Striatum and Cortex 
Spinal and Bulbar Muscular 
Atrophy (SBMA) 
Androgen receptor 
(AR) 
Nuclear and Cytoplasmic Motor Neurons 
Dentatorubal- Pallidoluysian 
Atrophy (DRPLA) 
Atrophin-1 Nuclear and Cytoplasmic Central Cortex 
Spinocerebellar ataxia 1 
(SCA1) 
Ataxin 1 Nuclear and Cytoplasmic Cerebellum 
Spinocerebellar ataxia 2 
(SCA2) 
Ataxin-2 Cytoplasmic Cerebellar Purkinje Cells 
Spinocerebellar ataxia 3/ 
Machado-Joseph disease 
(SCA3/MJD) 
Ataxin3 Nuclear and Cytoplasmic Cerebellum, Brain Stem, 
Basal Ganglia, Ventral pons 
and Substantia nigra  
Spinocerebellar ataxia 6 
(SCA6) 
Ataxin6 Nuclear and Cytoplasmic Cerebellar Purkinje Cells 
Spinocerebellar ataxia 7 
(SCA7) 
Ataxin7 Nuclear and Cytoplasmic Cerebellar Purkinje Cells, 
Brain Stem and Spinal Cord 
Spinocerebellar ataxia 17 
(SCA17) 
TBP Nuclear Cerebellar Purkinje Cells 
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The polyglutamine expansion diseases have onset in midlife, leading to the death of the 
patient 10-30 years after the appearance of the first symptoms (Cummings and Zoghbi, 2000; 
Orr and Zoghby, 2007; Macedo-Ribeiro et al., 2009). In general the age of onset inversely 
correlates with the size of expanded CAG repeats, and there are evidences that point to the 
interaction of the normal repeat with the expanded CAG repeat influencing the age of onset 
(Maciel et al., 1995; Maruyama et al., 1995; Gusella and MacDonald, 2000, Djousse et al., 2003).  
The genetic similarities among these disorders strongly support the hypothesis that these 
diseases share a common mechanism of pathogenesis, mainly based in the toxic properties of 
the polyglutamine tract. The expanded proteins of polyQ disorders have an enhanced ability 
to form intranuclear aggregates/inclusions (Ross and Poirer 2004), and in some cases also 
cytoplasmic inclusions in the disease affected regions (Ciechanover and Brundin, 2003; Bennet 
et al., 2005). Neuronal nuclear inclusions (NII) are considered to be a histopathological hall-
mark of the polyQ diseases. Although the role of nuclear inclusions in pathology is not com-
pletely understood, it is clear that these inclusions result from the nuclear accumulation of 
polyQ expanded proteins, which are normally in the cytoplasm. Mutant polyQ proteins in the 
nucleus can abnormally interact with nuclear proteins, such as transcription factors, leading 
to transcriptional dysregulation (Havel et al., 2009). The presence of these NI of mutant pro-
tein focused attention on the nucleus as the subcellular site determinant for the pathogenesis 
of these diseases, with some suggesting that inclusions were pathogenic (Arrasate et al. 2004) 
and others questioning this pathogenicity of aggregates/inclusions (Orr and Zoghbi, 2007). 
It is becoming more apparent that the polyQ tract by itself; even though toxic and suffi-
cient to cause polyQ pathology, does not account for all the symptoms of the polyQ disorders 
nor for all the similarities observed between them. It is possible that each polyglutamine dis-
order may be the result of the expanded polyglutamine tract action in the context of the 
“host” protein. This means that the normal function and the interactions of each polygluta-
mine protein is determinant to define the pathogenic pathway of each disorder, which ex-
plains the similarities found between disorders as well as their differences (Orr 2001; Gatchel 
& Zoghbi 2005; Orr and Zoghbi, 2007). 
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1.3. Spinocerebellar ataxias  
 Autossomal dominant Spinocerebellar Ataxias (SCAs) are a group of neurodegenerative 
diseases, with some of them being also polyglutamine disorders (SCA1, 2, 3, 6, 7 and SCA17) 
(Fig. 2). These disorders are clinically and genetically very divergent and are characterized by 
progressive cerebellar ataxia, which consists in the loss of motor coordination, showing 
unsteady movements and staggering gait (Zoghbi, 2000). Ataxia results from variable 
degeneration of neurons in the cerebellar cortex, brain stem, spinocerebellar tracts and their 
afferent/efferent connections. Although ataxia is the prominent symptom in SCAs, few 
mutations cause an almost pure cerebellar syndrome isolating neurodegeneration to the 
cerebellar cortex.  On the contrary, most SCAs are multisystemic disorders presenting clinical 
variability. The ataxia may be accompanied by numerous other symptoms that vary between 
different SCAs. One common ground between all of these diseases is the progressive 
neurodegeneration and its fatal outcome (Maruyama et al., 2002; Dueñas et al., 2006). 
 
Figure 2. Different CAG repeat expansions in Polyglutamine disorders.  (Adapted from Schöls et 
al., 2004). 
 The most striking characteristics in SCAs as unstable triplet expansion diseases are its 
unstable and heterogeneous expression, observed even in the same family (Moseley, 1998; 
Schöls, 2004); and the age of onset of the disease that is inversely correlated with the repeat 
length. The age of onset of the clinical symptoms is between 30 and 50 years of age, but there 
are cases of childhood onset caused by extreme expansions between generations. (Schöls et 
al., 2000; Zoghbi, 2000).  
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1.4. Machado Joseph Disease/Spinocerebellar ataxia 
type 3 
 Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most 
frequent autossomal dominantly inherited cerebellar ataxia worldwide, comprising between 
15% and 45% of all SCAs (Schöls et al., 1995; Riess et al., 2008). This neurodegenerative 
disease was first described in 1972 among immigrants native of the Portuguese Azorean 
Island, São Miguel. Later on, other cases were described in descents of Azorean immigrants 
from the Flores Island (Nakano et al., 1972; Rosenberg et al., 1976; Rosenberg et al., 1978); and 
the disorder was subsequently also identified in Brazil, Japan, China, and Australia (Sequeiros 
and Coutinho, 1993; Sudarsky and Coutinho, 1995). 
 MJD is caused by an unstable expansion of a CAG repeat in the coding region of the MJD1 
gene mapped on chromosome 14q32.1 (Kawaguchi et al., 1994). The MJD1 gene encodes 
ataxin-3, a 42 kDa protein that resides in both nucleus and cytoplasm (Paulson et al., 1997a). 
Ataxin-3 is a polyubiquitin-binding protein whose physiological function is related to 
ubiquitin-mediated proteolysis (Burnett et al., 2003; Chai et al., 2004). The mutation results in 
a long polyglutamine chain at the C-terminus of ataxin-3; the CAG repeats range from 10 to 44 
in normal population and from 45 to 87 in MJD patients (Cummings and Zoghbi, 2000; Maciel 
et al., 2001; Padiath et al., 2005) In MJD, like for other polyQ disorders, an inverse correlation 
between the number of CAG repeat and the age of onset of the disease is verified (Maruyama 
et al., 1995) 
 
 1.4.1. Genetic features  
 The common underlying genetic basis of MJD is the expansion of a CAG repeat region 
beyond a certain threshold. There is an overlap of normal repeat sizes (up to 47 repeats) in 
the CAG tract of the MJD1 gene. As shown in other polyQ diseases such as Huntington’s 
disease, individuals with a repeat length in the overlapping region do not always manifest the 
disease in what is designated as incomplete penetrance of the disease (Padiath et al., 2005). 
This repeat tract is not exclusively a CAG stretch, as variant CAA and AGG triplets were also 
found in normal alleles (Kawaguchi et al., 1994). 
 It was described somatic mosaicism of the repeat size in CAG repeat disorders, where 
different cells of the same individual carry different repeat sizes. This somatic instability has 
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also been described for MJD in different brain areas, there were found smaller repeat sizes in 
cerebellar cortex that in other brain regions (Lopes-Cendes et al., 1996; Hashida et al., 1997).  
 Even though the correlation between CAG repeats and the age at onset in MJD is well 
documented and proved to be a genetic feature of MJD, the length of CAG repeats does not 
account for all the variation observed in the patients. Also, the variance of the age at onset in 
MJD patients with similar number of repeats, suggest that additional factors influence the age 
at onset. It is predicted that a healthy life style leads to a later disease manifestation; it has 
also been shown that females manifest the disorder later in live as compared to their 
brothers even with the same expanded repeat size or longer normal CAG repeat sizes 
(DeStefano et al., 1995 ). CAG repeats are thought to be responsible for 45-60% of variability 
in age of onset, nevertheless other factors remain to be identified, and there is evidence that 
similarly to other polyQ diseases, proteic interactions may influence the variability observed 
in clinical phenotypes and age of onset (Maciel et al., 1995; Van de Warrenburg et al., 2002).  
 
 1.4.2. Clinical features 
 The clinical spectrum of MJD is highly pleomorphic. Based on these clinical manifestations 
four subphenotypes have been suggested (Coutinho and Andrade, 1978; Schöls et al., 1996; 
Riess et al., 2008), which during the progression of the disease may evolve from one type to 
other type (Fowler, 1984). Recently it an additional MJD type (V) has been proposed based in 
a homozygous 33-years old patient of Portuguese/Brazilian descent (Lysenko et al. 2010).  
Therefore the proposed five clinical subtypes of MJD are: 
 Type I: Extrapyramidal (dystonia and bradykinesia)+ Pyramidal deficits + early onset 
(10-30 years); 
 Type II: Pyramidal + cerebellar deficits + intermediate onset (20-50 years); 
 Type III: Cerebellar deficits + peripheral neuropathy + late onset (40-75 years); 
 Type IV: Neuropathy + Parkinsonism with variable onset; 
 Type V: Pronounced Extrapyramidal signs + Pyramidal deficits + spastic paraplegia + 
variable age of onset (4-43 years). 
 Other clinical features of MJD include ophtalmoplegia, double vision, faciolingual 
fasciculation, dysphagia, weight loss without loss of appetite, incontinence, restless legs 
syndrome, eyelid retraction, postural instability, difficulty with swallowing. Cognitive 
disturbances are mild and rarely develop to relevant dementia (Sequeiros and Coutinho, 1993; 
Sudarsky and Coutinho, 1995; Bürk et al., 2003). Clinically these symptoms may fluctuate in 
different subtypes according to individual characteristics, the number of CAGs and the age of 
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onset. For example, individuals with early onset of MJD may suffer more from dystonia and 
bradykinesia than from ataxia (type I). In addition, the latest onset patients, beginning after 
age 50, may experience as much difficulties resulting from neuropathy as from ataxia 
(Paulson et al., 2007; Riess et al., 2008). 
 
 1.4.3 Neuropathological features 
 The neuropathological alterations of MJD in the brain consist in neuronal loss in multiple 
systems. The degeneration is not confined to a single specific region of the brain, but on the 
contrary is quite widespread which contributes to the multiple clinical impairments observed 
in the disease. The disorder involves a combination of neurodegeneration in the 
spinocerebellar tract with other areas of the central nervous system (Fig. 3). The 
neuropathology involves cerebellar systems (dentate nucleus and pontine nuclei), cranial 
nerve motor nuclei, substantia nigra, and striatum. A relative preservation of the cerebellar 
cortex, particularly Purkinje cells at initial stages and inferior olive is reported (Rosenberg, 
1992; Coutinho and Andrade, 1995; Durr et al., 1996; Alves et al., 2008a). A marked 
degeneration of Clarkes’s column nuclei and vestibular and pontine nuclei is observed (Durr 
et al., 1996). Marked neuronal loss is also observed in the anterior horn of the spinal cord, 
and motor nuclei of the brainstem (Rub et al., 2008).  
 
Figure 3.  The main areas exhibiting neuronal loss in MJD. Indicated in the figure three of the most 
affected regions, the cerebellum, the ventral pons and substantia nigra. Large dots indicate severe neu-
ronal loss. Blue dots indicate involvement of extrapyramidal nuclei. Green dots indicate cranial nerve 
involvement.  (Adapted from Taroni and DiDonato, 2004) 
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 Studies regarding the localization of mutant ataxin-3 in the brain and its preferential 
accumulation allowed to describe with much more accuracy the regions affected by the 
disease itself. Upon macroscopic examination MJD patients brains (disease duration over 15 
years) display depigmentation of the substantia nigra, atrophy of the cerebellum as well as 
atrophy of cranial nerves III to XII. The depigmentation of the substantia nigra is the cause of 
parkinsonian features, however, not all the patients with degenerated substantia nigra show 
parkinsonism (Rub et al., 2003; Rub et al., 2006). The majority of these MJD patient’s brains 
has lower weight than brains from individuals without medical histories of neurological or 
psychiatric diseases (Iwabuchi et al., 1999). The study of human brains of normal individuals 
and MJD patients suggests that the cerebellar dentate nucleus and the substantia nigra are 
among early targets of the degenerative process of MJD, while the thalamus and the cranial 
nerves (dorsal motor vagal and ambiguous nuclei) are affected only late during the course of 
the disease (Riess et al., 2008).  The involvement of the striatum in the affected brain areas of 
MJD was recently described (Alves et al., 2008a) and may provide an explanation for 
symptoms found in some MJD patients such as dystonia and chorea (Lee et al., 2003). Chorea 
and dystonia have been consistently associated with lesions in the striatum. Chorea involves 
dysfunction of the indirect pathway from the caudate and putamen to the internal globus 
pallidus, whereas dystonia is generated by dysfunction of the direct pathway (Janavs et al., 
1998). 
 One important hallmark of neurodegeneration in the brains of MJD patients is the 
neuronal intranuclear inclusions (NIIs), which have been observed in patients, transgenic 
animal models and cellular models (Ikeda et al., 1996; Schmidt et al., 1998; Evert et al., 1999).  
The NIIs role in the pathogenesis is controversial. Initially associated to the pathogenic 
mechanism, they may actually contribute to delay the pathogenesis by concealing the toxic 
mutant ataxin-3 within inert structures reducing its toxicity. 
  
 1.4.4. MJD1 gene 
 The genetic locus for Machado-Joseph disease, MJD1, was identified in 1994 and mapped 
to chromosome 14q32.1 (Kawaguchi et al., 1994). The MJD1 gene spans about 48Kb with one 
long open reading frame (17776-base pairs) and is composed of 11 exons. It was identified as 
a novel gene containing CAG repeats that are located in exon 10 (Ichikawa et al., 2001). The 
normal MJD1 gene encodes ataxin-3 (ATXN3), a polyubiquitin-binding protein that is mutated 
in MJD. The mutation results in an expanded polyglutamine tract at the C-terminus of ataxin-
3 (Durr et al., 1996).  The CAG repeat contains two variant sequences, CAA and AAG, at three 
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positions that are also translated into a polyglutamine tract at C-terminal region of the 
protein ataxin-3. The normal allele of MJD1 has usually from 10 to 44 CAG repeats, there is an 
intermediate state where between 45 and 51 CAG repeats some individuals may manifest the 
disease and MJD patients alleles range from 52 up to 87 repeats (Cummings and Zoghbi, 2000; 
Maciel et al., 2001;Padiath et al., 2005). MJD’s high threshold is a particularity of this disorder 
since in other polyglutamine disorders repeats over 36 to 40 become pathogenic (Kawaguchi 
et al., 1994; Ichikawa et al., 2001; do Carmo Costa et al., 2004; Rodrigues et al., 2007).  
 
 1.4.5. Ataxin-3 
Human ataxin-3 is the MJD1 gene product, a ubiquitously expressed protein found in the 
genome of several species, ranging from nematodes to humans, and plants (Albrecht et al., 
2003). In mice and humans, despite the localized neuronal degeneration observed in MJD 
patients, ataxin-3 displays a ubiquitous expression among different body tissues and cell 
types. MJD1 was found to be widely expressed throughout the brain, though different regions 
present varying expression levels (Trottier et al., 1998). Although the precise biological func-
tion of ataxin-3 still remains poorly understood, evidence supports its participation in several 
pathways related to protein homeostasis maintenance (clearance of misfolded and damaged 
proteins) (Buchberger, 2002; Doss-Pepe et al., 2003; Burnett et al., 2003; Albrecht  et al., 2004; 
Chai et al., 2004; Mao et al., 2005; Berke et al., 2005), transcriptional regulation (Evert et al., 
2003; Rodrigues et al., 2007), cytoskeleton regulation (Rodrigues et al., 2010) and myogenesis 
(do Carmo Costa et al., 2010), cellular activities whose deregulation can compromise cell func-
tioning and survival. 
 
1.4.5.1. Structure 
The wild type ataxin-3 has an approximated globular weight of 42 KDa in normal individ-
uals, possesses 376 amino acids (including 22 glutamines of the polyQ tract) and is widely 
expressed in the brain and in the body existing in both nucleus and cytoplasm of various cell 
types (Paulson et al., 1997a; Trottier et al., 1998; Ichikawa et al., 2001). Ataxin-3 consists of a 
globular deubiquitinating N-terminal Josephin domain (20 KDa), able to resist proteolysis, a 
flexible protease accessible C-terminal containing two ubiquitin interacting motifs (UIM’s) 
and a polyQ region of variable length, whose expansion beyond a certain threshold is associ-
ated with MJD (Fig.4) (Burnett et al., 2003; Masino et al., 2003; Scheel et al., 2003). The most 
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common isoform found in the human brain has an extra UIM localized in the C-terminal re-
gion, downstream the polyQ sequence (Harris et al., 2010). The two conserved UIMs located 
N-terminally of the polyQ region are α-helical structures separated by a short flexible linker 
region and act cooperatively when binding ubiquitin (Ub); the affinity of the two tandem mo-
tifs is greater than that of each individual UIM (Song et al., 2010). 
 
Figure 4. Structure of the human Ataxin-3. Ataxin-3 is mainly composed of a conserved Josephin 
domain in the  N-terminal side, encoding the ubiquitin protease with the catalytic triad (Cys, His and 
Asn) and a Nuclear Export Signal (NES).  In the flexible C-terminal there are 2 or 3 ubiquitin-
interacting motifs (UIM), a Nuclear Localization signal (NLS) and the polyQ tract.   
 
A highly conserved, putative nuclear localization signal (NLS) is found upstream of the 
polyQ tract (Tait et al., 1998; Albrecht et al., 2004), this signal may determine the rate of atax-
in-3 transported into the nucleus but is shown to have a weak nuclear import activity (Antony 
et al., 2009). Furthermore, two nuclear nuclear export signals (NES) with significant activity 
were identified in ataxin-3, following the Josephin domain. (Antony et al., 2009; la Cour et al., 
2003). Even though the NLS has already been identified, the non-expanded protein is present 
both in the nucleus and in the cytoplasm; indicating that ataxin-3 possesses nucleocytoplas-
mic shuttling activity (Tait et al., 1998; Trottier et al., 1998; Antony et al., 2009). Evidences 
support the hypothesis that when in a non-aggregated state, the ataxin-3 polyQ is in a ran-
dom coil conformation (Chen et al., 2001). Polyglutamine abnormal expansion causes ataxin-3 
monomeric peptides to aggregate into β-rich amyloid-like fibrillar structures. The identity of 
pathogenic species remains unknown – whether the protein alone, the putative intermediates 
of the fibrillization pathway, or the soluble mature fibrils. Nevertheless, taking in account the 
similarities with other misfolding amiloidophaties it is possible that protofibrillar intermedi-
ates may be far more toxic than large aggregates (Gales et al., 2005). 
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Wild-type ataxin-3 is evenly distributed throughout the cell, particularly around the nu-
clear envelope, whereas mutant ataxin-3 accumulates into intranuclear aggregates and is 
depleted from the cytoplasm. Wild-type ataxin-3 co-localizes to ubiquitin-rich aggregates 
found in normal aged brains, known as Marinesco bodies (Fujigasaki et al., 2000), is also 
found in ubiquitinated inclusions of mutant polyQ proteins (Chai et al., 2001) and directly 
combined with the proteasome (Doss-Pepe et al., 2003). 
 
1.4.5.2. Ataxin-3 function 
Ataxin-3 is a de-ubiquitinating (DUB) enzyme present in the nucleus and in the cytoplasm 
of the cell that appears to function in cellular pathways regulating cellular vigilance, homeo-
stasis and transcriptional processes. DUBs are a group of enzymes responsible in the cell for 
removing ubiquitin (Ub) or polyUb chains from a target protein, processing Ub pre-proteins 
and remodeling or disassembling bound or unbound polyUb chains (Reyes-Turcu et al., 2009; 
Reyes-Turcu and Wilkinson, 2009). Ataxin-3 is an ubiquitin-binding protein capable of binding 
and cleaving specific types of large ubiquitin chains, removing ubiquitin from substrates to 
allow proteosomal degradation. Ataxin-3 binds to ubiquitin from polyubiquitinated sub-
strates by the UIM’s, allowing cleavage by ataxin-3 N-terminal Josephin domain. Ubiquitina-
tion fulfills many cellular functions in the cytoplasmic trafficking, guiding specific proteins 
through the endocytic pathways and targeting proteins for the proteasome (Buchberger, 
2002; Doss-Pepe et al., 2003; Burnett et al., 2003; Chai et al., 2004; Mao et al., 2005; Berke et al., 
2005). In the case of ataxin-3, inhibition of the catalytic activity results in the increase of 
polyubiquitinated proteins (localized primarily in the nucleus), to a degree similar to what is 
observed when the proteasome is inhibited (Berke et al., 2005). This supports the idea of 
ataxin-3 involvement with the polyubiquitinated proteins targeted for proteasomal degrada-
tion, therefore modulating ubiquitin-dependent mechanisms. 
These ataxin-3 characteristics suggested a possible role in the Ubiquitin-Proteasome Sys-
tem (UPS); the UPS is involved in the processing of mutant or damaged proteins (UPP), DNA 
repair, chromatin remodeling, cell cycle progression, subcellular localization and pathway 
signaling (Reyes-Turcu et al., 2009; Reyes-Turcu and Wilkinson, 2009; Weissman, 2001). Its 
impairment is related to several human diseases, such as polyQ diseases and other neuro-
degenerative pathologies. When the enzymatic activity of ataxin-3 is suppressed, it no longer 
can suppress abnormal protein’s toxicity and becomes somewhat toxic by itself leading to the 
impairment of the UPS, resulting in cell death (Burnett and Pittman, 2005). Considering its 
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function it is no surprise that several genes involved in the UPS vigilance pathway were al-
tered in the absence of wild-type ataxin-3 or in the presence of mutant ataxin-3 (Rodrigues et 
al., 2007). This evidence may be supported by the presence of ubiquitin in ataxin-3 aggre-
gates; that may be a consequence of ataxin-3 being itself a substrate for ubiquitination, and 
thus being degraded by the UPS (Matsumoto et al., 2004; Berke et al., 2005). 
Ataxin-3 function may also have relevance in the Endoplasmic Reticulum Associated Pro-
tein Degradation (ERAD). There is an ongoing controversia regarding whether ataxin-3 pro-
motes or decreases degradation by this pathway (Wang et al., 2006; Zhong and Pittman, 
2006); however, unexpectedly recent evidences suggest that ataxin-3 inhibits the ERAD, 
which can be explained by proteosomal degradation of ataxin-3 (Riess et al., 2008).  Ataxin-3 
has been found to associate with the proteasome itself through its N-terminal region (Doss- 
Pepe et al., 2003), but this interaction may not be very strong or even direct (Todi et al., 2007). 
Functioning with these interactors, ataxin-3 may act in a number of different ways, (a) trim-
ming polyUb chains of a substrate, thus facilitating the subsequent disassembly of the chain 
by proteasome-associated DUBs, (b) editing polyUb chains in order to guarantee that the sub-
strate is correctly targeted for degradation, or (c) functioning as a transiently associated sub-
unit of the proteasome and recognizing some of its substrates (Boeddrich et al., 2006; Wang et 
al., 2008).  
Another instance where ataxin-3 has been associated with cellular quality control mech-
anisms, is its proposed role in aggresome formation. Aggresomes are misfolded protein ag-
gregates that form near the microtubule-organizing center (MTOC) when the proteasome is 
not able to deal with misfolded proteins. These structures seem to be of physiologic im-
portance, since those defective proteins are then degraded by lysosomes, contributing to the 
maintenance of cellular homeostasis (Markossian and Kurganov, 2004). Endogenous ataxin-3 
seems to play a role in the regulation of aggresome formation, having been shown to co-
localize with aggresome and preaggresome particles and to be important in the formation of 
the aggresomes themselves (Burnett and Pittman, 2005). Ataxin-3 also associates with dynein 
and histone deacetylase 6 (HDAC6), both constituents of the complex responsible for the 
transport of misfolded proteins to the MTOC (Burnett and Pittman, 2005), and was recently 
shown to interact with tubulin and microtubule-associated protein 2 (MAP2), two other con-
stituents of the cytoskeleton (Mazzucchelli et al., 2009; Rodrigues et al., 2010). Along with its 
effect in increasing ataxin-3 catalytic activity, ubiquitination of this protein also potentiates 
its ability to promote aggresome formation (Todi et al., 2010). 
Interaction of ataxin-2 and ataxin-3 in Machado Joseph disease - Introduction 
 
Page | 14  
 
Considering the structure of ataxin-3, as well as its localization within the cell and its in-
teractions with other proteins, it is possible that ataxin-3 might be involved in transcriptional 
processes. Due to its characteristics, ataxin-3 has several ways of interacting with the tran-
scription. First and indirectly, through its DUB activity, ataxin-3 can modulate the degrada-
tion of transcription factors and repressors by removing the polyubiquitin degradation signal 
(Li et al., 2002). In addition, ataxin-3 may have a more direct effect over transcription regula-
tion since it has a NLS that allows its transportation to the nucleus, where it can regulate 
transcription. Recent studies demonstrated that ataxin-3 is actively transported across the 
nuclear envelope, being actively shuttled from the cytoplasm to the nucleus and vice versa 
(Chai et al., 2002; Antony et al., 2009; Macedo-Ribeiro et al., 2009). The nuclear accumulation 
of ataxin-3 following stress supports the hypothesis of a nuclear function such as transcrip-
tion regulation (Reina et al., 2010). Accordingly, it has also been suggested that ataxin-3 is 
able to bind histones through its Josephin domain and interact with histone acetyltransferas-
es, which work as transcriptional co-activators, thus repressing histone acetylation and tran-
scription.  Altered protein acetylation has already been implicated in polyQ disease processes 
(Li et al., 2002; Bodai et al., 2003; Zhang, 2003). The possible role of ataxin-3 in degradation 
pathways and in transcriptional regulation may be cell-specific, potentially explaining why 
only a subset of neurons is affected in the human disease despite the widespread expression 
of normal and mutant ataxin-3 (Rodrigues et al., 2007). 
The importance of ataxin-3 interaction with components of the cytoskeleton such as tu-
bulin, MAP2 and dynein may not be limited to its possible role in aggresome formation (Bur-
nett and Pittman, 2005; Mazzucchelli et al., 2009). Recent findings indicate that ataxin-3 may 
play a role in the organization of the cytoskeleton itself, since its absence leads to morpholog-
ic alterations in cell lines, which are accompanied by the disorganization of the several cyto-
skeleton constituents (microtubules, microfilaments and intermediate filaments) and a loss 
of cell adhesions (Rodrigues et al., 2010). 
Adding to these functions, in vitro silencing of ataxin-3 in differentiating mouse my-
oblasts, not only leads to the generation of an immature cytoskeleton, but also compromises 
myoblasts transition into muscle fibers, thus suggesting a potential role for ataxin-3 in myo-
genesis (do Carmo Costa et al., 2010). This process comprises several events where remodel-
ing of the cytoskeleton as well as of cell–cell and cell–extracellular matrix interactions is of 
crucial importance, with a tight control of protein expression and turnover (frequently by the 
UPP) being essential (Baylies and Michelson, 2001; Bryson-Richardson and Currie, 2008). 
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1.4.6. Nuclear inclusions and pathogenesis mechanisms 
 Since the association between polyglutamine expansions and neurodegeneration was 
made (La Spada et al., 1994), a number of mechanisms had been suggested to participate in 
the pathology of these diseases such as altered gene expression (Okazawa, 2003), impairment 
of cell’s quality control machinery: proteasome and chaperones (Ferrigno and Silver, 2000) 
and alterations in intracellular trafficking and apoptotic cell death (Rego and de Almeida, 
2005). 
 1.4.6.1. Nuclear inclusions 
 A common feature of polyglutamine diseases is the deposition of insoluble intracellular 
inclusions containing the misfolded disease protein (Paulson, 1999). Although their 
correlation with pathology is controversial (Bates, 2003; Michalik and Van Broeckhoven, 
2003), nuclear and sometimes cytoplasmic inclusions are considered the identifying hallmark 
of polyglutamine diseases (Ross and Poirier, 2004).  The type of aggregated proteins and the 
regional and cellular distribution of the protein deposits vary from disease to disease, 
indicating that the individual proteins carrying the polyglutamine expansion modulate the 
associated pathogenesis (Paulson, 2003).  
 Mutant ataxin-3 in MJD, like other pathogenic proteins with expanded polyQ tracts, 
appears to undergo a conformational alteration and aggregate in cells forming ubiquitinated 
intranuclear neuronal inclusions (NIIs) with many different neurons containing more than 
one inclusion body, both in and outside areas affected by the selective neurodegeneration 
(Paulson et al., 1997b; Schimdt et al., 1998; Rub et al., 2006). Ataxin-3 aggregates were shown 
to contain -rich fibrillar structures of amyloid nature (Bevivino and Loll, 2001; Chen et al., 
2002). As for most amyloid-forming proteins, several pathways may drive the conversion of 
the soluble protein to amyloid aggregates, through the formation of different 
conformationally altered monomeric or self-assembled multimeric species (Uversky, 2010). 
Polyglutamine monomers of ataxin-3 acquire β-strand conformations that have been shown 
to be cytotoxic in cultured cells (Nagai et al., 2007), assembling into oligomers (Bevivino and 
Loll, 2001; Takahashi et al., 2008) able to simultaneously dissociate into monomers (Schaffar 
et al., 2004).  Thus, it seems that β-stranded polyglutamine monomers are important for 
pathogenesis in MJD and other polyglutamine diseases, however is still controversial if their 
toxicity is sufficient to be neurotoxic. Polyglutamine oligomers, have been shown to induce 
greater toxicity than polyglutamine monomers or inclusion bodies in neuronaly 
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differentiated cells (Takahashi et al., 2008). This and other findings support the hypothesis 
that polyglutamine oligomers may have a crucial role in cytotoxicity (Poirier et al., 2002; 
Sanchez et al., 2003; Kayed et al., 2003; Ross and Poirier, 2004; Behrends et al., 2006), as well as 
β-stranded monomers, however the role of amyloid fibrillar aggregates is still controversial 
as well as the NIIs in the pathogenesis of the disease (Popiel et al., 2011)(Fig. 5 ). 
 
Figure 5. Inclusion bodies formation. Proteins with an expanded polyQ stretch are prone to misfold 
into a β-sheet dominant structure, leading to their assembly into oligomers and amyloid fibrillar ag-
gregates, followed by their accumulation as inclusion bodies within neurons, eventually resulting in 
neurodegeneration. Dashed arrows indicate structures for which cytotoxicity remains controversial. 
(Adapted from Popiel et al., 2011). 
 
 NIIs are eosinophilic structures, which vary in size from 0.7 to 3.7 µm; are membrane-
bound and contain a mix of granular and filamentous structures. These aggregates were also 
found in the cytoplasm of neurons in several affected areas (Hayashi et al., 2003), and in 
axons in fiber tracts known to be targets of neurodegeneration in MJD (Seidel et al., 2010). 
Nuclear inclusions of mutant polyglutamine proteins are characteristic of these diseases. 
Even in those diseases where the aggregates are found in cytoplasm like in SCA2 and SCA6, 
there is evidence for the presence of polyQ inclusions in the nuclei of neuronal cells (Ishikawa 
et al., 2001; Pang et al., 2002; Schols et al., 2004). The nuclear membrane serves as barrier 
segregating activities related to gene transcription from other activities of the cytoplasmic 
compartment. This function does not exclude its part in the cellular mechanisms of these 
polyQ diseases, in fact, it has been more accepted that the functional and structural changes 
in the nucleus are central for the pathogenesis of several neurodegenerative diseases.  The 
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presence of NII is the proof that the neuronal nucleus suffers changes that allows the nuclear 
aggregation of certain proteins that in their normal conformation are localized in the 
cytoplasm (Woulfe, 2007).  
 In NIIs, normal and mutant ataxin-3 colocalize with cellular components such as ubiquitin, 
the proteasome, heath shock proteins (HSPs) and transcription factors (Cummings et al., 
1998; McCampbell et al., 2000; Schmidt et al., 2002). Other proteins have also been found in 
the NIIs of pontine neurons of MJD patients, such as ataxin-2 (the causative protein of SCA2) 
and the TATA box binding protein (TBP) (Uchihara et al., 2001). 
 The NIIs in MJD are distributed in many neurons of the central and peripheral nervous 
regions, including the cerebral cortex, thalamus and autonomic ganglia (Schilling et al., 1999). 
However, the presence of NIIs in regions not affected in MJD raises the possibility that NIIs 
are not directly pathogenic (Rub et al., 2006). It has been suggested that NIIs are in fact just 
the result of protective cellular mechanisms to cope with the toxicity of the expanded 
proteins. Studies concerning MJD demonstrate that there is no perfect overlap between the 
brain regions that degenerate and the regions presenting NIs (Klement et al., 1998; Saudou et 
al., 1998; Cummings et al., 1999; Evert et al., 2006; Paulson et al., 1997b; Ross and Poirier, 2004; 
Trottier et al., 1998; Yamada et al., 2001). Interestingly, upon blockage of the ubiquitin 
machinery fewer inclusions are observed but neurodegeneration proceeds. Therefore the 
mutant proteins may be far more toxic if they are not sequestered into inclusions, which 
supports the hypothesis that NIIs formation can be a protective mechanism against the 
toxicity of polyQ expanded proteins (Schols et al., 2004). 
 
 1.4.6.2. Pathogenesis mechanisms 
 Although in different levels, SCAs show as a common characteristic the progressive 
neurodegeneration and mutant proteic aggregate formation, which accumulate in the nucleus 
or in the cytoplasm. Despite the fact that the causative genes are widely expressed, the 
central nervous system is commonly and selectively attained, with neurodegeneration 
patterns that are unique to each disease.  The inherited ataxias are caused by either gain of 
function or loss of function mutations in seemingly unrelated genes. Because of the overlap in 
the phenotypes and the prominence of the Purkinje cells pathology, it is hypothesized that 
the gene products involved in this class of neurodegenerative diseases might play a role in 
common molecular pathways that are essential for cerebellar function and survival (Gatchel 
and Zoghbi, 2005)(Fig. 6).  
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Figure 6. Mechanisms of pathogenesis in Machado-Joseph disease. Expanded polyglutamine 
proteins might mediate pathogenesis trough a range of common mechanisms; MJD is no exception. The 
MJD1 gene with expanded CAG repeat is transcribed and translated into ataxin-3 with expanded 
polyglutamine tract. The expansion results in an aberrant structure of ataxin-3, which forms possible 
new proteic interactions that wouldn’t happen in normal situation and triggers several events that lead 
to neurodegeneration in selective areas of the brain. Accumulation of mutant ataxin-3 to form 
insoluble NIIs recruits components of the UPS and other protein quality-control pathways, 
furthermore, the normal function of ataxin-3 in the cell can contribute to the impairment of UPS, thus 
leading to a dysfunction in these quality-control mechanisms. The full-length polyglutamine protein 
can also be cleaved by proteases to form fragments, which are toxic and might also mediate pathogenic 
effects. The oligomerization and aggregation and the posttranslational modifications may also 
contribute to the increase of the neuronal cytotoxicity and dysfunction. The mutant protein affects 
many other cellular processes, including transcription and RNA metabolism. Other cellular processes 
that can be affected include mitochondrial function, calcium homeostasis, and axonal transport, 
ultimately leading to neuronal dysfunction and death. Q, glutamine; Ub, ubiquitin. (Adapted from 
Gatchel and Zoghbi, 2005) 
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1.5. Ataxin-3 interactions  
 Several studies reported the importance of protein-protein interactions in understanding 
the normal function of the disease-causing proteins (Yoshida et al., 2002; Chen et al., 2003; 
Goehler et al., 2004; Ravikumar et al., 2004; Kaytor et al., 2005; Tsuda et al. 2005); thus 
suggesting that interactions between ataxin-3 and other proteins could be important in the 
development of MJD pathogenesis. 
 One of the most intriguing facts that points to a possible protein interaction of Ataxin-3 
with other proteins is the age of onset. As previously referred an inverse correlation between 
the number of CAG repeats and the age of onset is present in MJD. The CAG repeats are 
responsible for most of the variability in the age of onset (about 45-60%) (Maciel et al., 1995; 
Van de Warrenburg et al., 2002). Nevertheless, there are cases where this correlation it is not 
verified suggesting that other factors can contribute to the age of onset.  
 Another evidence that not only the CAG repeats account for the phenotype is the 
variability in the symptoms and overall phenotype of heterozygous individuals with similar 
number of CAG repeats. As previously discussed, CAG repeats are thought to be responsible 
for some part of the variability but there is a lack of evidence about other factors that can 
influence the phenotype and the disease progression. In other polyQ diseases correlations 
between specific proteic interactions and the variability of the phenotypes and diseases 
progression have been reported. It has been suggested that also in MJD proteic interactions 
can determine certain aspects of the disease and be the cause of the divergence observed 
(DiStefano et al., 1995; Maciel et al., 1995; Van de Warrenburg et al, 2002). 
 Studies revealed that silencing of the mutant Ataxin-3 is not enough to stop the pathology, 
leading to a diminished inclusion formation but unable to stop completely the pathogenesis 
of the disease (Hübener and Riess, 2010). This phenomenon could imply that pathogenesis is 
related to other factors besides the action of the mutant ataxin-3, becoming more clear the 
possible role of other proteins interacting with ataxin-3 in MJD. Moreover, the toxicity might 
be related with the expanded polyglutamine tract, but this does not explain the selective 
vulnerability of specific neurons affected in MJD. Thus, the normal function of ataxin-3 and 
protein-protein interaction mechanisms might also be crucial for pathogenesis (Takahashi et 
al., 2010). 
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 1.5.1. Ataxin-3 interaction with other polyglutamine 
proteins 
 Among the SCAs, there is a remarkable overlap of symptoms, including progressive loss 
of gait and limb muscle coordination, with neurodegeneration in the cerebellum and often 
brainstem nuclei (Paulson, 2007). In addition to the shared mechanism of mutation and 
several phenotypes, there are intriguing hints of interactions between the polyglutamine 
genes that cause different SCAs.  
 For example, relatively long CAG repeats lengths (within the normal range) in the 
causative gene for SCA6 are correlated with an early age of onset of SCA2 (Pulst et al., 2005). 
Moreover, between SCA2 and SCA3 there are also some observations that suggest links 
between the causing genes. A phenotypic characteristic in SCA3 patients is correlated with 
the length of CAG repeat in the normal alleles of SCA2 causing gene (Simón-Sanchez et al., 
2005). Both SCA2 and SCA3 are unusual among the dominantly inherited ataxias in that they 
can manifest with parkinsonism (Jardim et al., 2003). The normal ataxin-2 (Atx2) protein can 
be detected in the pathogenic inclusions of SCA3 patients, and, likewise, normal ataxin-3 
protein localizes to the inclusions formed in SCA2 patients (Uchihara et al., 2001). In a search 
for modifiers of degeneration induced by the human pathogenic protein causing SCA3, the 
ataxin-2 gene was identified (Bilen and Bonini, 2007). The normal activity of Ataxin-2 was 
shown to be critical to SCA3 neurodegeneration, suggesting that toxicity of one polyglutamine 
disease protein can be modulated by the normal activity of another (Lessing and Bonini, 
2008). The causing gene for SCA2 (ataxin-2) had already been associated to SCA1, in a search 
for genetic modifiers for this disease (Fernández-Funez et al., 2000). This genetic interaction 
between these two causing polyQ diseases was shown to be due to physical direct interaction 
(Lim et al., 2006). However, it has been suggested that ataxin-2 and ataxin-3 do not interact 
with each other directly (Lim et al. 2006) and may be dependent of an additional transcript 
target. The ataxin-2 protein is thought to be related with regulation of translation of specific 
transcripts (Satterfield and Pallanck, 2006), taking into account that ataxin-2 physically 
interacts with poly-A-binding protein (PABP) in polyribosomes (Ralser et al. 2005) and with 
putative RNA-binding protein: ataxin-2-binding-protein (A2BP) (Shibata et al. 2000). 
However, it seems that ataxin-3 mRNA cannot be directly the target of ataxin-2-PABP 
interaction (Lessing and Bonini, 2008). Nevertheless, other proteins could be implicated in 
this interaction. In fact, network studies of ataxia-causing proteins revealed hub proteins that 
interconnect several proteins, including several ataxia-causing proteins (Baravabi and Albert, 
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1999; Lim et al. 2006). Three of these proteins seem to be very relevant and important: RBM9, 
A2BP1, and RBPMS. The last two proteins were found to be genetic modifiers of SCA1 
(Fernández-Funez et al., 2000). Also, these three proteins are involved in RNA binding or 
splicing (Jin et al., 2003; Nakahata and Kawamoto, 2005; Underwood et al., 2005). Finally, 
these three proteins interact together in an ataxia-causing protein network, linking ataxin-1, 
ataxin-2 and ataxin-3 (Lim et al., 2006). 
 Several studies have revealed the importance of protein-protein interactions in 
understanding the normal function of the disease-causing protein (Stefan et al., 2001; Yoshida 
et al., 2002; Chen et al., 2003; Goehler et al., 2004; Ravikumar et al., 2004; Kaytor et al., 2005; 
Tsuda et al. 2005). Unraveling the molecular mechanisms underlying these interactions could 
lead to identification of new targets and pathways that could be used as therapeutic 
approaches. 
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1.6. Ataxin-2 
Human Ataxin-2 (ATX2) is the gene product of the spinocerebellar ataxia type 2 (SCA2) 
gene. This gene was localized to chromosome 12q24.1 in 1993 but it was not until 1996 that 
Ataxin-2 was identified as its product (Gispert et al., 1993; Pulst et al., 1996; Sanpei et al., 
1996). The SCA2 gene contains 25 exons, encompassing approximately 130kb of genomic 
DNA (Sahba et al., 1998) and it has an unstable triplet-repeat expansion as the pathogenic 
mutation, coding for a polyglutamine domain in the N-terminal region of the protein Ataxin-2. 
This triplet-repeat reads (CAG)8-CAA-(CAG)4-CAA-(CAG)8 in DNA and mRNA of most individ-
uals, but can vary in length in the human population. The presence of more than 31 triplets in 
the SCA2 gene may cause clinically manifest neurodegeneration (Pulst et al., 1996; Sanpei et 
al., 1996; Pulst et al., 2005). 
 
1.6.1 Ataxin-2 Structure 
Ataxin-2 is composed of 1312 amino acid residues (including the 22 glutamines of the 
polyQ stretch), with an approximated molecular mass of 140kDa. Except for the polygluta-
mine domain in its N-terminal, ATX2 has no similarity with other proteins involved in poly-
glutamine diseases (Albrecht et al., 2004). Ataxin-2 is a highly basic protein with an isoelectric 
point of 9.6 due to the elevated content in glutamine residues, the 22 glutamines are flanked 
by a region of proline-rich and serine-rich domains. The protein is not exclusively basic, con-
taining one acidic region of 46 acidic amino acids (amino acid 254-475). This region covers 
roughly exons 2-7 and is predicted to consist of two globular domains named Lsm (Like Sm, 
amino acid 254-345) and LsmAD (Lsm- associated domain, amino acid 353-475) (Fig. 7) 
(Neuwald et al., 1998). 
The Lsm domain contains Sm1 and Sm2 motifs, which are found in proteins involved in 
RNA splicing, suggesting that wild-type ataxin-2 might function as a component of the RNA 
splicing complex. The LsmAD with mainly α-helices, contains both a clathrin-mediated trans-
Golgi signal and a endoplasmic reticulum exit signal (Neuwald et al., 1998; Huynh et al., 2003; 
Albrecht et al., 2004). Ataxin-2 also has a highly conserved domain in its C-terminal, which 
mediates association with the polyadenylate (poly(A))-binding protein, PABP (Fig. 6). This 
domain is called PAM2, which stands for PABP interacting motif, due to its function. This do-
main is contained in a number of proteins including an ataxin-2 ortholog, Ataxin-2 related 
protein (A2RP) (Kozlov et al., 2001). 
Interaction of ataxin-2 and ataxin-3 in Machado Joseph disease - Introduction 
 
Page | 23  
 
 
Figure 7. Protein structure of human ataxin-2. The PolyQ tract in the N-terminal region, the two 
globular domaisn, Lsm and LsmAD domains, and the PAM2 motif in the C-terminal region.  
  
 1.6.2. Ataxin-2 function 
Many of the proteins affected by polyQ expansions normally function as transcription fac-
tors and the transcriptional dysregulation appears to be a central feature of the neurodegen-
erative mechanism in the disease (Hughes et al., 2001). Ataxin-2 is one of these polyQ pro-
teins, implied directly in SCA2, and in a dominantly inherited form of Parkinsonism (Shan et 
al., 2001; Lu et al., 2004). More recently it has been implicated in the neurodegenerative dis-
eases ALS (Elden et al., 2010) and SCA1 (Al-Rahami et al., 2007). This makes ataxin-2 an im-
portant and interesting protein by the suggestion that in its wild type form it can be a modu-
latory protein for other diseases. Therefore ataxin-2 may be an important key to understand 
the disease mechanisms and possibly allow the discovery of new and promising therapeutic 
targets. However, despite the several studies conducted to understand wild type ataxin-2 
function, it is still currently not fully understood. Previous work on ataxin-2 and its related 
homologues, have implicated this protein in diverse biological processes including secretion, 
cell specification, actin filament formation and apoptotic and receptor-mediated signaling. 
Several observations suggest that the influence of the ataxin-2 in all these processes results 
from a conserved biochemical function in cytoplasmic RNA metabolism (He et al., 2000; Sat-
terfield and Pallanck, 2006).  
A role of ataxin-2 in RNA metabolism is credible in view of the Lsm and LsmAD domains 
contained in its N-terminal. The Lsm domain is known to function as an RNA-binding domain 
to Lsm proteins that are generally involved in important processes of RNA metabolism, in-
cluding RNA modification, splicing and degradation. Ataxin-2 may fulfill similar functions in 
RNA metabolism. Ataxin-2 interacts with the translational machinery by assembling with 
polyribosomes through its Lsm/LsmAD domain and independently through its PAM2 motif 
(He et al., 2000; Satterfield and Pallanck, 2006).   
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Ataxin-2 functions may be accessed by its interactions with other proteins; to achieve 
that, several studies were conducted using ataxin-2 homologous.  From these studies it be-
came clear the role of this protein in RNA metabolism, observed specially by its interaction 
with PABP and polyribossomal machinery. 
 
1.6.2.1 Stress granules (Ataxin-2 and PABP co-localization 
site) 
It has been demonstrated that ataxin-2 is a component of mammalian stress granules 
(Ralser et al., 2005). Stress granules (SG) are cytoplasmic sites where untranslated mRNAs 
are stalled during environmental stress, and both RNA stabilizing and destabilizing proteins 
such as PABP are recruited to stress granules. PABP is found in distinct cytoplasmic granules 
(stress granules) arising in the cytoplasm of mammalian cells in response to environmental 
stresses (Kedersha and Anderson, 2002; Villace et al., 2004). Preliminary genetic analyses of 
Ataxin-2 and its homologs indicate that the role of this gene family in RNA metabolism may 
involve translational regulation. Ataxin-2 was co-localized with PABP in stress granules, 
which demonstrated that ataxin-2 is a part of these in heat stressed cells. It is possible that 
ataxin-2 may be recruited to the SG so that PABP can perform its normal function of RNA 
modification. Since it was discovered that ataxin-2 is a component of these sites of mRNA 
triage, one might speculate that ataxin-2 plays a role in regulating cellular mRNA turnover 
(Ralser et al., 2005). 
Another protein localized to the stress granules was TDP-43 that interestingly interacts 
with ataxin 2 in ALS (Liu-Yesucevitz et al., 2010), as we discuss ahead. The regulatory role of 
ataxin-2 in the SGs, and the interaction with TDP-43 and SGs, is likely to reflect a mixed 
mechanism involving both protein-protein interactions, as well as protein-RNA interactions, 
since TDP-43 is a well known protein interactor with ataxin-2 (Hua and Zhou, 2004; Nonhoff 
et al., 2007). The type of interaction might depend on the particular species of TDP-43 and on 
the conditions at the binding site. A recent study demonstrated that ataxin-2 binds TDP-43 
and expanded polyglutamine domains in ataxin-2 promote formation of TDP-43 inclusions. 
The same group also identified cases of ALS that were TDP-43 positive and associated with 
expanded polyglutamine stretches in ataxin-2. SG proteins might enhance inclusion for-
mation related to these proteins as a result of their mutual associations (Elden et al., 2010). 
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1.6.2.2. A2BP1 
Further strengthening the concept of ataxin-2 function in RNA metabolism; it has been 
shown that the C-terminus of ataxin-2 binds to A2BP1 (Shibata et al., 2000), a novel protein 
containing a RNP motif which is highly conserved among RNA-binding proteins (Ralser et al., 
2005) and whose RNA-binding C. elegans homologue, fox-1, regulates tissue-specific alterna-
tive splicing (Jin et al., 2003). Disruption of the human A2BP1 gene may cause epilepsy or 
mental retardation (Bhalla et al., 2004). A bulk of evidence indicates that ataxin-2 homo-
logues might be involved in RNA splicing, mRNA stabilization or degradation and other essen-
tial RNA-processing pathways. Further studies are required to define its function in RNA me-
tabolism (Ralser et al., 2005). 
 
1.6.3. Ataxin-2 localization 
Ataxin-2 has a widespread expression in adult and embryonic tissues, predominantly in 
the brain, but also in the heart, muscle, intestine, liver and lung (Pulst et al., 1996). Ataxin-2 is 
strongly expressed in neuronal cells of adult mouse brain such as large pyramidal neurons 
and subpopulations of hippocampus, thalamus and hypothalamus. Its major localization is 
seen in the cerebellar Purkinje cells, the primary site of SCA2 neurodegeneration (Nechiporuk 
et al., 1998). 
In its normal distribution was found in apical cytoplasm of pyramidal neurons of 
some layers of the frontal cortex, but not in white matter (Huynh et al., 1999). In the hippo-
campus, ataxin-2 is more expressed in pyramidal neurons than in the granule neurons of the 
dentate gyrus. In the basal glia, in the neurons of globus pallidus and amygdaloid nuclei, a 
moderate ataxin-2 expression was found (Huynh et al., 1999). In the large neurons of substan-
tia nigra a strong expression was found, as well as in the cerebellum. In Purkinje cells a 
strong expression of ataxin-2 was observed whereas in the dentate nucleus this expression 
was moderate (Huynh et al., 1999; Lastres-Becker et al., 2008). Recurring to fluorescent label-
ing, it was observed that in Purkinje cells, the expression of ataxin-2 besides intense was dis-
tributed throughout the cells including the dendrites with an intense labeling around the nu-
cleus, with the particularity of being concentrated in only one pole of the cytoplasm (Huynh et 
al., 1999; Becker et al., 2008). 
The levels of Ataxin-2 expression increased with age in neurologically normal brains 
and were greatly increased in brains from SCA2 patients (Huynh et al., 1999). 
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1.7. Ataxin-2 proteic interactions 
Despite the genetic heterogeneity, many ataxias show striking similarities. These 
similarities suggest that SCAs, and perhaps other ataxias, may also share common mecha-
nisms of pathogenesis. Interaction proteic networks can explain the phenotypic similarities in 
inherited cerebellar ataxias (Lim et al., 2006; Soong and Paulson, 2007). Several ataxia pro-
teins interact together and there are common processes and pathways involved in this class 
of neurodegenerative diseases. A surprising and interesting outcome of its study was that the 
majority (18/23) of the ataxia-causing proteins interact either directly or indirectly with 
each other (Lim et al., 2006). 
 
1.7.1 Ataxin-2 mediates Ataxin-1 induced neuro-
degeneration 
Spinocerebellar ataxia type 1 (SCA1) is caused by the expansion of a CAG repeat encoding 
the polyQ tract within the protein ataxin-1, which induces a toxic gain of function (Orr and 
Zoghbi, 2001). Although the polyglutamine expansion triggers the toxicity of ataxin-1, exper-
iments in Drosophila and mouse SCA1 models have shown that protein context plays a de-
terminant role in expanded ataxin-1 induced neurodegeneration (Gatchel and Zoghbi, 2005). 
In addition, certain interacting partners of unexpanded ataxin- 1 are critical to the expanded 
ataxin-1 toxicity (Tsai et al., 2004; Tsuda et al., 2005; Al-Rahami et al., 2007). 
Expanded ataxin-1 by itself causes an abnormal phenotype in the Drosophila eye and 
overexpression of ataxin-2 also leads to an abnormal eye phenotype. Upon co-expression of 
the two ataxins, an increase in the severity of the phenotype was observed. Decreased levels 
of endogenous ataxin-2 also modified expanded ataxin-1 toxicity. However nor the SCA1 
mRNA transcripts nor the levels of ataxin-1 protein were affected by altering the levels of 
ataxin-2. Flies with expanded ataxin-1 in the nervous system displayed a progressive im-
pairment of motor function, which was suppressed by the decrease of ataxin-2 levels. SCA1 
flies heterozygous for an ataxin-2 mutation showed a significantly improved motor perfor-
mance when compared to flies with normal ataxin-2 (Al-Rahami et al., 2007). It was also ob-
served that ataxin-1 is able to precipitate endogenous ataxin-2 from human cells, which sug-
gests that these proteins may be functional interactors in vivo (Al-Rahami et al., 2007). 
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Regarding subcellular localization, ataxin-1 is normally found in the nucleus while ataxin-
2 is clearly a cytoplasmic protein.  In neurons, endogenous ataxin-2 is not normally found in 
the nucleus but when co-expressed with expanded ataxin-1, it was possible to observe ataxin-
2 in the nucleus. These results indicate that expanded ataxin-1 causes ataxin-2 to localize to 
the nucleus and suggest that both proteins co-aggregate in NIIs. This accumulation in the nu-
cleus occurs when the expanded ataxin-1 is present and is not promoted in the presence of 
unexpanded ataxin-1. . Ataxin-2 accumulation is paticularly harmful in the nucleus where it 
contributes to the exacerbated toxicity of expanded ataxin-1. This nucleoshuttling of ataxin-2 
into the nucleus is an important mechanism of SCA1 pathogenesis (Al-Rahami et al., 2007). 
 
1.7.2 Ataxin-2 intermediate-length polyglutamine ex-
pansions are a risk factor for ALS 
Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig’s disease, is a progressive, 
fatal neurodegenerative disease caused by degeneration of motor neurons (Cleveland et al., 
2001). To date, various genes have been identified as associated with familial cases, among 
these, mutations in superoxide dismutase 1 (SOD1), which account for 15–20% of cases of 
familial ALS (Valentine et al., 2003). Transactivate reponse DNA-binding protein (TARDBP, or 
TDP-43) is a major disease protein of the ubiquitin-positive cytoplasmic inclusions in ALS 
without SOD1 mutations (Neumann et al., 2006; Winton et al., 2008). Ataxin-2 was found to be 
a possible modifier of TDP-43 toxicity in ALS (Elden et al., 2010), since the motor neurons 
features of SCA2 are sufficiently prominent to mimic an ALS presentation, indicating the po-
tential for a clinicopathological overlap (Infante et al., 2004; Nanetti et al., 2009). 
Pbp1, the ortholog of human Ataxin-2 gene, was identified as a gene that enhanced TDP-
43 toxicity. Upregulation of Pbp1 enhanced TDP-43 toxicity in yeast, whereas Pbp1 loss-of-
function suppressed toxicity. It was also observed that mutant TDP-43 aggregates in the cy-
toplasm were able to recruit Ataxin-2 (Elden et al., 2010). 
Recent observations in patients with ALS indicate that intermediate-size expansions 
(polyQ27-33) of ataxin-2 act as a risk factor modulating the manifestation and age at onset of 
motor neuron degeneration (Chen et al., 2011; Daoud et al., 2011; Elden et al., 2010; Lee et al., 
2011; Ross et al., 2011; Soraru et al., 2011; Van Damme et al., 2011). Regarding the effects of 
ataxin-2 in the pathogenesis of ALS, it was observed that ataxin-2 expansions just above the 
threshold (Q32–37) may lead to ALS instead of SCA2 (Daoud et al., 2011; Ross et al., 2011). 
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1.8. Ataxin-2 connection to PABP determines its func-
tion?  
Pbp1 (PABP binding protein 1) is the yeast homologue of human ataxin-2, a non-essential 
protein in contrast to Caenorhabditis elegans and Drosophila melanogaster homologues, 
which were proven to be essential proteins. Ataxin-2 shows significant homology to the yeast 
protein Pbp1, which also contains the Lsm and LsmAD domains. The regions outside of these 
two globular domains are predicted to be mainly unstructured in Pbp1 as in ataxin-2 (Fig. 8) 
(Albretcht et al., 2004). Although the C-terminal tail of Pbp1 does not contain a PAM2 motif, 
this yeast protein regulates polyadenylation after pre-mRNA splicing and interacts with the 
C-terminal part of the yeast homologue Pab1 of the human cytoplasmic poly(A)-binding pro-
tein 1 (PABP) (Mangus et al., 1998). Ataxin 2-binding protein 1 (A2BP1) and PABP are also 
evolutionarily related and possess RNA recognition motifs (Shibata et al., 2000). These obser-
vations strongly suggest that ataxin-2 is involved in similar mRNA processing tasks (Albrecht 
et al., 2004). 
 
Figure 8. Protein structures of human Ataxin-2 and its yeast homologue Pbp1. Both proteins have 
a putative RNA binding Lsm domain followed by an as yet uncharacterized Lsm-associated domain 
LsmAD. ATX2 also contains a PABC-interacting motif named PAM2, which Pbp1 does not contain. 
(Adapted from Ralser et al., 2005). 
 
Pbp1 regulates polyadenylation and binds the C-terminal part of the poly(A)-binding pro-
tein Pab1, the yeast homolog of human cytoplasmic poly(A)-binding protein 1 (PABP). In the 
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absence of Pbp1, the 3’- ends of the pre-mRNAs are cleaved properly, but lack a complete 
poly(A) tail (Mangus et al., 1998; Mangus et al., 2003; Mangus et al., 2004). Pbp1 is linked to 
the nuclear export machinery of mRNA (Nakielny and Dreyfuss, 1997), therefore taking in 
account its structural and functional similarity with ataxin-2, it is possible to extrapolate that 
ataxin-2 is also linked to this function.  
C. elegans ataxin-2 homolog, ATX2, is widely expressed in the cytoplasm in form of a 
complex together with a poly(A)- binding protein (PAB1) (Ciosk et al., 2004). The complex 
formed suggests a possible role for ATX2 in PAB1 mediated processes. However, not all PAB1 
functions were affected by the silencing of ATX2, raising the hypothesis that ATX2 does not 
play a mandatory role in all of PAB1 functions and may instead have specialized functions. 
ATX2 seems to be responsible for the ability of PAB1 to interact with components of the 
translational machinery, therefore playing an important role in the translation regulation as 
suggested in studies with other homologues. It was also shown that reduced ataxin-2 function 
was able to alter the abundance of particular proteins, without altering the abundance of 
their corresponding transcript, suggesting that these transcripts may be translationally regu-
lated by ataxin-2 (Ciosk et al., 2004). Several studies achieved similar evidences that loss of 
ataxin-2 increases the abundance of some proteins while reducing the abundance of others, 
suggesting that the possible regulatory role in translation can be both positive and negative 
(Ciosk et al., 2004; Satterfield and Pallanck, 2006). 
A direct interaction between ATX2 and PAB1 was not shown in C. elegans. Nevertheless, 
this possible interaction was found upon transfection of mammalian cell lines (COS-1) with 
ATX2 since endogenous PABP and ATX2 are present in the cytoplasm of COS-1 cells, and co-
localize in certain areas of the cytoplasm (Ralser et al., 2005). Noticeably, it seems that ATX2 
(C. elegans ataxin-2 homologous) and Pbp1 (yeast ataxin-2 homologous) use different mech-
anisms to interact with the C-terminal part of PABP and Pab1, respectively. While ATX2 binds 
the PABC domain itself, the major interaction site of Pbp1 with Pab1 appears to be a region 
preceding the PABC domain of Pab1 (Mangus et al., 2004). 
Despite the evidence that the ATXN2 family is involved in translational regulation, there 
was no direct evidence that ataxin-2 would engage the translational apparatus and itself 
function as a translational regulator. Later it was, demonstrated that human ataxin-2 and its 
Drosophila homolog (ATX2) interact with the translational machinery by assembling with 
polyribosomes (Satterfield and Pallanck, 2006), suggesting that the ataxin-2 protein directly 
influences the translation of particular mRNAs. ATX2 bears at least two polyribosome binding 
regions, one envolving the N-terminal Lsm/LsmAD domain and the other the C-terminal 
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region (PAM2 motif), thus its assembly is mediated independently by the Lsm/LsmAD 
domains and the PAM2 motif. The Lsm portion of the Lsm/LsmAD domain is a known RNA-
binding motif and could thus allow ataxin-2 to directly bind to polyribossomal mRNA; 
whereas ataxin-2 assembles with PABP in a PAM2 motif dependent manner and its 
interaction appears to link ataxin-2 to polyribosomes by allowing it to interact with the 
polyribosome-bound dPABP (Satterfield and Pallanck, 2006). 
Given the evidence supporting a role for Ataxin-2 in translational regulation, the question 
arises to the mechanism by which ataxin-2 imposes this regulation. The cytoplasmic localiza-
tion of ataxin-2 indicates that this protein most likely does not influence directly transcrip-
tion, but its interaction with PABP as well as its assembly with polyribosomes, seem to be 
solid indicators of an ataxin-2 role in the mediation of translational regulatory activities. 
 
1.8.1. PABP 
The poly(A)-binding protein (PABP) is a highly conserved, abundant and essential protein 
which can shuttle between the nucleus and the cytoplasm of all eukaryotes exhibiting differ-
ent functions depending on its location in the cell (Afonina et al., 1998; Brune et al., 2005). It is 
a ubiquitous RNA-binding protein, which preferentially associates with the 3’-poly(A) tail of 
eukaryotic mRNA (Amrani et al., 1997). This multifunctional protein is involved in an exten-
sive range of cellular functions, including translation, mRNA metabolism, and mRNA export 
(Afonina et al., 1998; Brune et al., 2005). 
Structurally, PABPs consist of four N-terminal RNA-recognition motifs (RRMs) and a C-
terminal that consists in a proline-rich region and a globular domain termed PABC (Fig. 9) 
that has been shown to be important for functional regulation by interacting with many cyto-
solic and nuclear proteins (Kozlov et al., 2001). In humans, three types of PABP proteins are 
observed: cytoplasmic PABPs (PABPC1, PABPC3, and iPABP); nuclear PABP (PABPN1); and X-
linked PABP (PABPC5).  PABC structure plays an important and determinant role in the cellu-
lar localization of PABP (Kleene et al., 1998; Mangus et al., 2003). 
Interaction of ataxin-2 and ataxin-3 in Machado Joseph disease - Introduction 
 
Page | 31  
 
 
Figure 9. PABP1 structure diagram. The N-terminal consists in the four RRMs, different and not 
functionally equivalent. The C-terminal consists in a proline rich region and the PABC. (Adapted from 
Smith and Gray, 2010). 
 
 The RRMs associate with the poly(A) tail of mRNA and can also act as a scaffold for bind-
ing other proteins, which appear to differ in their RNA- and protein-binding specificities 
(Mangus et al., 2003; Gorgoni et al., 2004).  The association of PABPs with poly(A) requires a 
minimal binding site of 12 adenosines, and multiple PABP molecules can bind to the same 
poly(A) tract, forming a repeating unit covering approximately 27 nucleotides (Baer et al., 
1983; Sachs et al., 1987).  PABPs interact with poly(A) via RNA-recognition motifs (RRMs). 
Because of the essential function of the RRM domains, they have received more attention 
than the PABC domain. The C-terminal of PABP does not bind RNA, but is required for oli-
gomerization. Both C-terminal regions bind proteins, but the PABC domain, in particular, me-
diates interactions with proteins that contain a PAM2 motif to regulate translation and mRNA 
stability (Roy et al., 2002; Albrecht and Lengaver, 2004; Bravo et al., 2005). There are many 
proteins that have a PAM-2 motif, ataxin-2 for example. Each modulates translation efficiency 
via interaction with PABP, other translation factors, or cis-elements within the mRNA tran-
script. The structures of PABC domain adopt a comparable fold consisting of four or five α- 
helices and act in an analogous manner by recognizing a similar PAM-2 sequence. The human 
PABC-PAM2 complex structure displays the PAM-2 motif binding to specific residues within 
the PABC domain (Kozlov et al., 2004).  
PABPs have crucial roles in the pathways of gene expression. They bind the poly(A) tails 
of newly synthesized or mature mRNAs and appear to act as cis-acting effectors of specific 
steps in the polyadenylation, export, translation, and turnover of the transcripts to which 
they are bound (Mangus et al., 2003). As an initiator factor, PABP plays a global role in the 
translation of adenylated mRNAs. However, the translation of some mRNAs is more sensitive 
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to PABP than others (Smith and Gray, 2010). In addition to its global activity, PABP also has 
specific roles in translation. PABP binding to internal poly(A) stretches in 3’-UTRs can pro-
mote translation (Skabkina et al., 2003). PABP can also be recruited to the 3’-UTR to activate 
translation by direct protein-protein interactions (Mangus et al., 2003).  
Moreover, PABP participates in mRNA turnover and stability. Removal of the poly(A) tail 
is the initial step in different mRNA turnover pathways an PABP-mediated end-to-end initia-
tion complexes generally protect the poly(A) tail from deadenylases and block deccaping. 
Lacking any evident of catalytic activity, PABPs provide a scaffold for the binding of factors 
that mediate these steps and also apparently act as antagonists to the binding of factors that 
enable the terminal steps of mRNA degradation (Mangus et al., 2003).  
Therefore, PABP principal function is related to global gene regulation both by stimulat-
ing translational initiation and by enhancing RNA stability (Sachs and Davis, 1989; Wang and 
Kiledjian, 2000). Its connection to ataxin-2 through the PAM2 motif places PABP in an inter-
esting position, since it is the only known protein to bind ataxin-2 through that motif.  The 
observed role of ataxin-2 in translational regulation may therefore be mediated by its connec-
tion to PABP.  
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1.9. Ataxin-2 may mediate Ataxin-3 induced neuro-
degeneration in MJD/SCA3 
Mutant polyQ proteins in the corresponding diseases are found to be aggregated with 
similar chaperones besides the proteasome subunits; which may imply the sharing of im-
portant pathogenic features (Bilen and Bonini, 2007). This established common ground in the 
pathogenesis of these neurodegenerative diseases opened the door for the study of proteic 
interactions as modifiers of the toxicity mechanisms involved in several diseases. A number 
of modifiers of polyQ disease proteins have been already identified using animal models; in-
cluding chaperones, transcriptional co-regulators and microRNAs. Several studies have been 
conducted trying to unravel potential modulators of ataxin-3 (Kazemi-Kazemi-Esfarjani and 
Benzer, 2000; Fernandez-Funez et al., 2000; Nollen et al., 2004; Bilen et al., 2006). Ataxin-3 is a 
unique protein due to its implication in ubiquitin pathways and degradation pathways. These 
characteristics not only make ataxin-3 an interesting protein regarding possible proteic in-
teractions but also convert these studies searching for modifiers in a determinant tool to un-
derstand MJD and provide potential therapeutic targets to this disease that is the most fre-
quent SCA.  
 Heat shock proteins (Hsp) were already involved in ataxin-3 toxicity in studies with 
Drosophila. Hsp70 substantially ameliorated Ataxin-3 retinal toxicity in a model of SCA, 
whereas the expression of a dominant negative form of Drosophila Hsp40, enhanced retinal 
toxicity (Warrick et al., 1999).  In a screening study to search modifiers of ataxin-3 toxicity, 
the majority of modifiers fell into chaperone and ubiquitin pathways, consistent with ataxin-3 
function in the UPS (Bilen and Bonini, 2007). 
 As previously discussed, ataxin-2 participates as a modulator in some disorders in-
cluding PolyQ diseases modulating the neurodegeneration induced by expanded ataxin-1 in 
SCA1 and, in its intermediate length form, increasing the risk for ALS. Another study revealed 
that ataxin-2 intermediate expansions also modulated the risk of another neurodegenerative 
disorder within the spectrum of Parkinson-plus syndromes, progressive supranuclear palsy 
(Ross et al., 2011). Several lines of evidence led researchers to consider ataxin-2 as holder of a 
strong potential as a common mediator in neurodegenerative diseases (Ghosh and Feany, 
2004). 
 In SCA1 and MJD some overlap has been observed in the symptoms due to the same 
affected areas (Ghosh and Feany, 2004). Different genes that modify SCA1 toxicity have been 
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shown to encode proteins that interact directly with pathogenic ataxin 1, and further, to form 
an interaction network that includes ataxin-3 (Lim et al., 2006). Is it possible that similarly to 
what happens with ataxin 1, ataxin-2 may also influence the pathogenesis of MJD by interact-
ing with ataxin-3?  
Several evidences support the hypothesis that ataxin-2 may act downstream of ataxin-3 
in shared pathways, a concept strengthened by the parallels between the following neuro-
degeneration syndromes. Similar to the polyQ-expansions of sizes ≥34 in the mutant ataxin-2 
causing SCA2, polyQ expansions of sizes ≥52 in the ataxin-3 (ATXN3) cause MJD. In both SCAs 
the pattern of affected neuron populations extends beyond the spinocerebellar circuits to 
involve the peripheral and central motor neurons as well as the dopaminergic neurons of 
substantia nigra (Munoz et al., 2002; Lastres-Becker et al., 2008). In consequence, SCA2 and 
MJD usually manifest with ataxia and dysarthria in their clinical pictures. As a result of the 
affection of dopaminergic nigra neurons, a clinical presentation of levodopa- responsive Par-
kinsonism can be present, caused both by ataxin-2 and ataxin-3 expansions in SCA2 and MJD, 
respectively (Gwinn-Hardy et al., 2000, 2001; Shan et al., 2001; Payami et al., 2003; Simon-
Sanchez et al., 2005; Lu et al., 2006; Socal et al., 2009). Due to the motor neurons degeneration, 
the manifestation of prominent areflexia may be present in combination with pyramidal signs 
mimicking ALS, which may be caused by polyQ expansions in ataxin-2 and in ataxin-3 (Lan-
dau et al., 2000; Infante et al., 2004; Rosa et  al., 2006; Pinto de Carvalho, 2008; Nanetti et al., 
2009). Interestingly, ALS-typical inclusion bodies containing TDP-43 were observed in the 
cytoplasm of affected motor neurons both in SCA2 and in MJD (Tan et al., 2009; Elden et al., 
2010; Seidel et al., 2010), suggesting the possibility of common pathogenic mechanisms for 
these disorders.  In addition to all of these evidences, ataxin-2 can be detected in the NII in 
neurons of MJD patients as well as ataxin-3 can be reported in SCA2 inclusions, suggesting 
that these two proteins share some type of connection, otherwise this would not be observed 
(Uchihara et al., 2001; Lessing and Bonini, 2008). It was also found a correlation between the 
length of the CAG repeat length at the SCA2 gene and fasciculations in MJD patients (Jardim et 
al., 2003). 
In the Drosophila eye the presence of mutant expanded ataxin-3 by itself induced degen-
eration, but when coexpressed with ataxin-2 a dramatical enhancement in the degeneration 
was verified. In contrast, when the levels of ataxin-2 where reduced a significant mitigation of 
degeneration was observed. Similar results were observed in Drosophila neurons (Lessing 
and Bonini, 2008). Taken together, these studies suggest that normal endogenous ataxin-2 
activity facilitates ataxin-3 dependent toxicity, with up-regulation of ataxin-2 enhancing and 
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loss of ataxin-2 functions dramatically slowing the progression of neurodegeneration caused 
by pathogenic ataxin-3. The formation of NIIs as a hallmark of polyglutamine disease was also 
correlated with these previous reports. Up-regulation of ataxin-2 which enhanced ataxin-3 
toxicity, also accelerated inclusion formation when compared to the inclusions in animals 
expressing solely mutant Ataxin-3 (Lessing and Bonini, 2008). 
 To further clarify the mechanism by which ataxin-2 modulated ataxin-3 in Drosophila, 
it was tested whether the PAM2 motif of ataxin-2 was required for the enhancement of MJD 
toxicity. The PAM2 motif is required for ataxin-2 to associate with PABP, and together with 
the RNA-binding Lsm domain, it mediates colocalization of ataxin-2 with PABP in polyribo-
somes. Using an ataxin-2 lacking its PAM2 motif it was observed that this motif was determi-
nant for the accelerated inclusion formation, since the coexpression of this ataxin-2 and mu-
tant ataxin-3 did not induce the results observed earlier on the study with normal and com-
plete ataxin-2 (Lessing and Bonini, 2008). 
 Because PABP is the only protein known to date to interact directly with ataxin-2 
through its PAM2 motif, its involvement in MJD neurodegeneration became a possibility. Us-
ing flies expressing mutant ataxin-3 and with deletion of the PABP gene, an enhancement in 
degeneration of the Drosophila eye was observed. On the contrary, overexpression of PABP 
significantly suppressed neurodegeneration. These results suggested that PABP has an oppo-
site activity to ataxin-2 with respect to ataxin-3 dependent neurodegeneration, playing a pro-
tective role. Further tests were conducted revealing that the toxicity of ataxin-2 is mitigated 
by PABP, therefore consistent with PABP also playing a crucial role in modulating ataxin-3 
toxicity. The importance of the PAM2 motif for ataxin-2’s toxicity and for the enhancement of 
ataxin-3 neurodegeneration suggests a mechanism of interaction between these two pro-
teins, even though indirect. PABP is possibly the connection between these two proteins since 
ataxin-2 does not interact directly with another known protein through its PAM2 motif.  It 
may happen that in the absence of the connection of PABP to the PAM2 motif of ataxin-2, 
there would be an induction of MJD neurodegeneration by ataxin-2 action. When this interac-
tion occurs, the PAM2 motif is blocked and it may have a suppressor effect on ataxin-2 action 
in MJD neurodegeneration (Lessing and Bonini, 2008). 
 These findings point to an interaction between the gene that causes SCA2 and the 
gene responsible for MJD, leaving the suggestion of a determinant role of PABP as a mediator 
of this interaction. This interactive and regulative proteic network may be a key to underline 
new therapeutical strategies and unravel further therapeutic targets. Nevertheless, further 
studies are necessary to confirm these observations in mammalian models. 
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Objectives 
The general objective of this work is the evaluation of the modulator effect of ataxin-2 
and PABP in Machado-Joseph disease, concerning a possible interaction between these pro-
teins and Ataxin-3.  
The specific objectives are as follows:  
 To study Ataxin-2 and PABP levels in Machado-Joseph disease patient tissue. 
 To analyze Ataxin-2 and PABP levels in a transgenic mouse model of Machado-Joseph 
disease. 
 To study how overexpression of Ataxin-3 modulates Ataxin-2 and PABP expression in 
cellular models of Machado-Joseph disease. 
 To investigate the effects of Ataxin-2 and PABP overexpression in cellular models of Ma-
chado-Joseph disease, regarding the expression levels of Ataxin-3, Ataxin-2 and PABP.  
 To investigate if silencing PABP in a cellular model of Machado-Joseph disease aggra-
vates the pathogenesis of the disease.  
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Chapter II 
Methods and Material 
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2.1. Tissue preparation 
2.1.1. Human  
 Postmortem cortex and striatal tissue from three MJD patients with morphologically 
and genetically confirmed MJD (1: 62 years, 26/70 CAG repeats; 2: 53 years, 23/69 CAG 
repeats; 3: 62 years, 22/74 CAG repeats) were obtained from the “Tissue donation program 
of the National Ataxia Foundation, Minneapolis, MN, USA” (VA Medical Center, Albany, N.Y., 
USA). Two controls with no evidence of neurological disease (1: 55 years; 2: 56 years) were 
obtained from Neurology and Pathology Services of University Hospital of Coimbra (H.U.C). 
The tissue was fresh when dissected and then placed in 10% neutral buffered formalin and 
kept at 4ºC. 
 The tissue was cryopreserved in 25% sucrose- 0.1M PBS solution for 48h. The tissue 
was then dry-ice frozen and cut at a cryostat-microtome (Leica CM3050S, Leica Microsystems 
Nussloch Gmbh, Nussloch, Germany) in 25-30 µm coronal sections. Slices were collected and 
stored in 48-well trays (Corning Inc., NY, USA), free-floating in 0.1M PBS supplemented with 
0.12 µmol/L sodium azide. The plates were stored at 4°C until the immunohistochemical 
processing.  
 
2.1.2. Transgenic and Wild-type Mice 
The Machado Joseph’s disease transgenic mouse model expressing the N-terminal-
truncated ataxin-3 with 69 glutamine repeats and an N-terminal hemagglutinin (HA) epitope 
driven by Purkinje-cell-specific L7 promoter (Tg-MUT) was previously described ( Torashima 
et al., 2008; Oue et al., 2009). A colony of these transgenic mice was established in the Center 
for Neurosciences and Cell Biology of the University of Coimbra and the line was maintained 
by backcrossing heterozygous males with C57BL/6 females. Genotyping was performed by 
PCR. The present study used 6 heterozygous animals and 6 wild-type.  
Transgenic mice (Q69) and wild type C57BL/6 mice, with 14 weeks old, were killed 
by sodium pentobarbital overdose, transcardially perfused with 0.1M PBS and a 4% 
paraformaldehyde fixate solution (PFA 4%, Fluka, Sigma, St. Louis, USA) followed by brain 
removal. After retrieving cerebellar punches, the tissue was cryoprotected in 25% sucrose- 
0.1M PBS solution for 48h, dry ice- frozen and cut at a cryostat-microtome (Leica CM3050S, 
Leica Microsystems Nussloch Gmbh, Nussloch, Germany) in 20 µm coronal sections. Slices of 
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each animal were collected in superfrost plus microscope slides (Thermo Fisher Scientific, 
U.S.A) and stored at -20°C before immunohistochemical processing. 
Brains of wild type C57BL/6 mice and transgenic mice (Q69) (Torashima et al., 2008), 
with 14 weeks old were dissected fresh; and small punches of striatum, cortex, hipocamppus 
and cerebellum were collected; the punches were harvested with a Harris Uni-Core pen, with 
2.0 mm of diameter (Ted Pella, Inc, CA, USA) and kept at -80°C.  
 
2.1.3. Lentiviral-based MJD rat model 
In the lentiviral-based MJD rat model, LV encoding human full length wild-type (Atx3-
27Q) (Alves et al., 2008b) and human full length mutant ataxin-3 (Atx3-72Q) (Alves et al., 
2008b), were stereotaxically injected into striatum of anesthetized animals.  
 Two (n=3), four (n=3) and eight (n=3) weeks after injection in the striatum (4 weeks 
old at the time of the injection), the animals were killed by sodium pentobarbital overdose, 
transcardially perfused with 0.1M PBS and a 4% paraformaldehyde fixate solution (PFA 4%, 
Fluka, Sigma, St. Louis, USA) followed by brain removal. The tissue was cryoprotected in 25% 
sucrose- 0.1M PBS solution for 48h, dry ice- frozen and cut at a cryostat-microtome (Leica 
CM3050S, Leica Microsystems Nussloch Gmbh, Nussloch, Germany) in 20µm coronal sections.  
Three slices of each animal were collected and stored in 48-well trays (Corning Inc., NY, USA), 
free-floating in 0.1M PBS supplemented with 0.12 µmol/L sodium azide. The plates were 
stored at 4°C until immunohistochemical processing.  
 
 
 
 
 
 
 
Interaction of ataxin-2 and ataxin-3 in Machado Joseph disease – Methods and Material 
 
 
2.2. Cell cultures 
2.2.1. Neuroblastoma cell culture 
Mouse neuroblastoma cell line (Neuro-2a cells) obtained from the ATCC cell biology 
bank (CCL-131) were incubated in DMEM medium supplemented with 10% FBS, 100U/ml 
penicillin and 100µg/ml streptomycin (Gibco, Paisley, Scotland, UK) (complete medium) at 
37°C in 5% CO2/air atmosphere.  
2.2.2. Human fibroblasts culture 
Human fibroblast cells were obtained from Coriel cell repositories and skin biopsy 
(Control: 38 years, not affected; MJD1: 38 years, 74 CAG repeats; MJD2: 28 years, 82 CAG 
repeats). Cells were kept in culture in DMEM supplemented with 10% bovine serum, 1% non 
essential amino-acids, 2mM L-glutamine 100U/ml penicillin and 100µg/ml streptomycin 
(Gibco, Paisley, Scotland, UK) (complete medium) at 37°C in 5% CO2/air atmosphere. Cells 
were then plated in 12-wells plaque and 12-weels plates with slides, at 48h post-plating cells 
were lysed for western blotting and the plaque with slides was fixated with PFA 4% for 
immunocitochemistry. 
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2.3. Infection/Transfection 
2.3.1. Lentiviral vectors 
Viral vectors encoding for the human Ataxin-2, PABP, human full length wild type 
ataxin-2 with 27 glutamines (ATX3 WT) (Alves et al., 2008b) and human full length mutant 
ataxin-3 with 72 glutamines (ATX3 MUT) (Alves et al., 2008b) were produced in human 
embryonic kidney cells (HEK) 293T cells using a four-plasmid system described previously 
(de Almeida et al., 2002). The lentiviral particles were produced and resuspended in 
phosphate-buffered saline with 0.5% bovine serum albumin (PBS-BSA) and samples were 
matched for particle concentration by measuring HIV-1 p24 antigen content (RETROtek, 
Gentaur, France). Viral stocks were stored at -80°C until use. 
 
2.3.2. N2A infection   
 Mouse neuroblastoma cell line (Neuro-2a cells) obtained from the ATCC cell biology 
bank (CCL-131) were incubated in DMEM medium supplemented with 10% FBS, 100U/ml 
penicillin and 100µg/ml streptomycin (Gibco, Paisley, Scotland, UK) (complete medium) at 
37°C in 5% CO2/air atmosphere. We plated the cells in 12 well plates; 2 x 105 cells per well in 
1000µl of medium and 24h later were infected with lentiviral vectors.  
 For the infection, we replaced the medium with 400µl of new medium and 1.6µl of 
hexadimethrin bromid (Aldrich) (8µg/ml) and added the corresponding lentivirus according 
to the condition (human full length wild type ataxin 3, human full length mutant ataxin-3, 
human ataxin-2 and human PABP), the plates were then incubated at 37°C in 5% CO2/air 
atmosphere, and after 6h of infection, we added 600µl of new fresh medium to the wells. At 
two weeks post-infection cells were lysed for western bloting analysis.  
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2.3.3. Lipofectamine transfection  
Mouse neuroblastoma cell line (Neuro-2a cells) were incubated in DMEM medium 
supplemented with 10% FBS, 100U/ml penicillin and 100µg/ml streptomycin (Gibco, Paisley, 
Scotland, UK) (complete medium) at 37°C in 5% CO2/air atmosphere. Cells were plated in a 
24 well plaque and 24 hours later were lipofectamine transfected. For the transfection we 
plate 2 x 105 cells in 500µl of growth medium without antibiotics per well. 0.8µg of DNA 
(shPABP and shLuc accordingly with the situation) were diluted in 50µl of Opti-MEM® I 
Reduced Serum Medium without serum. Also diluted 2.0µl of Lipofectamine TM 2000 
(Invitrogen, CA, USA) in 50µl of Opti-MEM and incubated both mixtures for 5min at room 
temperature. After the 5 min incubation, we combined the two mixtures and incubated for 
more 20min at room temperature, allowing the DNA-Lipofectamine TM 2000 (Invitrogen, CA, 
USA) complexes to form. Next the 100µl of the mixture were added to each well and the 
plaques were incubated at 37°C in 5% CO2/air atmosphere, after 4h the medium was changed 
back to DMEM with FBS. At 48h post-transfection cells were lysed for western blot analysis.  
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2.4. Immunochemical procedures  
2.4.1. Immunohistochemistry for human brain tissue  
 The immunohistochemical procedure for human tissue was initiated by mounting the 
sections in superfrost plus microscope slides (Thermo Fisher Scientific, U.S.A) followed by the 
drying of those slides at 37°C approximately 45min. Once dried the sections were incubated 
30min at 100°C with a Tris-buffered saline (TBS) pH 9 antigen retrieval solution and then 
blocked for 1h at room temperature in a 0.3% Triton in PBS solution supplemented with 10% 
NGS. After the blocking, sections were incubated with monoclonal mouse anti-ataxin-2 
antibody (BD Biosciences, San Jose, California, USA) diluted in the blocking solution (1:1000, 
overnight 4°C). After the overnight incubation, the sections were washed three times with 
PBS and incubated with the corresponding secondary antibodies anti-mouse conjugated to 
alexa 488 or 594 fluorophores (Alexa Fluor, Invitrogen, Paisley, UK) diluted in 0.1% Triton in 
PBS supplemented with 10% NGS for 2h at room temperature. The sections were washed 
three times with PBS after the incubation, counterstained with DAPI and mounted with 
Fluorsave (Calbiochem, Germany). Fluorescent images were acquired with a Zeiss Axiovert 
200 imaging microscope or LSM Zeiss microscope for double staining. All 
immunohistochemical analyses were performed in triplicate and for an n=3 for MJD patients 
and n=2 for controls. 
 
2.4.2. Immunohistochemistry for Transgenic and Wild-
type mouse sections 
The immunohistochemical procedure was initiated by drying the slides with the 
sections at 37°C for 1 h., followed by hydratation with PBS and 1h at room temperature 
blocking in 0.3% Triton in PBS supplemented with 10% of NGS (normal serum goat, Gibco). 
After the blocking, sections were incubated with the appropriate antibodies diluted in the 
blocking solution: mouse monoclonal anti-ataxin-2 antibody (BD Biosciences, San Jose, 
California, USA.; 1:1000, overnight 4°C) and mouse monoclonal anti-PABP antibody 
(Millipore, Temecula, California, USA;1:1000, overnight 4°C). After the overnight incubation, 
the sections were washed three times with PBS and incubated with the corresponding 
secondary antibodies goat-mouse conjugated to alexa 488 or 594 fluorophores (Alexa Fluor, 
Invitrogen, Paisley, UK) diluted in 0.1% Triton in PBS supplemented with 10% NGS for 2h at 
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room temperature. The sections were washed three times with PBS after the incubation, 
counterstained with DAPI and mounted with Fluorsave (Calbiochem, Germany).  Fluorescent 
images were acquired with a Zeiss Axiovert 200 imaging microscope. All 
immunohistochemical analyses were performed in triplicate; for the sections incubated with 
ataxin-2 there was an n=6 and for those incubated with PABP there was an n=5. 
 
2.4.3. Free-floating Immunohistochemistry for Lentiviral-
based MJD rat model sections 
  Free-floating immunochemistry was initiated incubating brain sections on 
phenylhidrazine diluted in PBS (1:1000; 15min, 37°C) for peroxidase inhibition, followed by 
three washes with PBS (5’; 5’; 10’). Once washed the sections were blocked 1h at room 
temperature in PBS 0.1% Triton solution with 10% NGS and then incubated overnight with 
the primary antibodies: rabbit polyclonal anti-ataxin-3 antibody (Immunostep, Salamanca, 
Spain; 1:2000, overnight 4°C);  mouse monoclonal anti-ataxin-2 antibody (BD Biosciences, 
San Jose, California, USA; 1:1000, overnight 4°C)  and mouse monoclonal anti-PABP antibody 
(Millipore, Temecula, California, USA; 1:1000, overnight 4°C). After the overnight incubation, 
the sections were washed three times with PBS and incubated with the corresponding 
secondary antibody goat-mouse  and rabbit conjugated to alexa 488 or 594 fluorophores 
(Alexa Fluor, Invitrogen, Paisley, UK) diluted in blocking solution (1:200) for 2h at room 
temperature.  The sections were washed three times with PBS after the incubation, 
counterstained with DAPI, premounted in superfrost plus microscope slides (Thermo Fisher 
Scientific, U.S.A) followed by a drying period of approximately 45min at 37°C. Once dried the 
sections were mounted with Fluorsave (Calbiochem, Germany). Light images were acquired 
with a Ziess Axiovert 200 imaging Microscope. All immunohistochemical analyses were 
performed in triplicate and using three sections of each animal with at least two or three 
snaps per section, three animals per each period of time (2W, 4W and 8W).  
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2.4.4. Immunohistochemistry quantitative analysis 
 The human brain tissue analysis for the ataxin-2 positive cells was carried out 
counting for each staining, eight fields (x200 magnification) of three different sections. 
Cytoplasmic puncta-like immunoreactivity positive for ataxin-2 were counted by means of 
image analysis software (ImageJ, National Institute of Health, USA). Measurements were 
performed in triplicate and results are represented as the mean value of ataxin-2 positive 
punctuates per section ±SEM. 
The lentiviral-based model rat sections analysis for the ataxin-2, PABP and ataxin-3 
positive cells were carried out counting for each staining, eight fields (x100 magnification) of 
three different sections per each period of time evaluated.  
The transgenic and wild-type mouse sections analysis for ataxin-2 and PABP positive 
cells were carried out counting for each staining, eight fields (x400 magnification). 
Measurements were performed in triplicate and results are represented as the mean value of 
ataxin-2 and PABP immunoreactivity per section ±SEM. 
 
2.4.5. Immunocitochemistry of human fibroblasts 
Human fibroblasts were plated in 24-wells plates with slides; at 48h post-plating cells 
were fixated with PFA 4% for immunocitochemistry.  
To initiate the immunocitochemistry, cells were permeabilized with PBS 1% Triton 
solution (5min; 500µL per well) and then washed with PBS. Once washed it was performed 
the blocking in a solution of PBS with 3% BSA for 1h at room temperature. Primary 
antibodies mouse monoclonal anti-ataxin-2 (BD Biosciences, San Jose, California, USA) and 
mouse monoclonal anti-PABP (Millipore, Temecula, California, USA) conjugated with rabbit 
polyclonal anti-ataxin-3 (Immunostep, Salamanca, Spain) accordingly to the situation, were 
diluted in the blocking solution (1:100) and incubated overnight at 4°C. After the overnight 
incubation, we incubated with the corresponding secondary antibodies anti-mouse 
conjugated to alexa 488 or 594 fluorophores (Alexa Fluor, Invitrogen, Paisley, UK) diluted 
(1:200) in PBS 1% BSA for 2h at room temperature. The sections were washed three times 
with PBS after the incubation, counterstained with DAPI and mounted with Fluorsave 
(Calbiochem, Germany). Light images were acquired with a Ziess Axiovert 200 imaging 
Microscope. All immunocitochemical analyses were performed in triplicate; with two slides 
per situation and at least 12 snaps per slide, at the same exposure in the same day. 
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2.4.6. Immunocitochemistry quantitative analysis 
The fibroblast slides analysis for the ataxin-2, PABP and ataxin-3 positive cells were 
carried out counting for each staining, several fields (x400 magnification) of two slides for the 
different conditions. Ataxin-2 and PABP immunoreactivity was measured per cell and per 
nucleus. Measurements were performed in triplicate and results are represented as the mean 
value of ataxin-2 and PABP immunoreactivity per slide ±SEM. 
 
2.5. Protein extraction and Western Blotting 
For the protein extraction protocol, brain tissue and cells were lysed in RIPA-buffer 
solution (50mM Tris HCl pH 8, 150nM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS) containing proteases inhibitors (Roche diagnostics GmbH, Mannheim, Germany) 
followed by a 4s ultra-sound chase (1 pulse/s). Protein concentration was determined with 
the Bradford protein assay (BioRad, Munich, Germany). Depending on the analysis, twenty 
(Neuro-2a), forty (mouse brain punches) and sixty (human fibroblasts) micrograms of 
protein extract were resolved in SDS-polyacrylamide gels (8% or 12% accordingly with the 
analysis). The proteins were transferred onto PVDF membrane (GE Healthcare, Amersham, 
UK) according to standard protocols (Alves et al., 2008b). The membranes were blocked by 
incubation in 5% nonfat milk powder in 0.1% Tween 20 in Trisbuffered saline (TBS-T) for 1 h 
at room temperature, and were then incubated overnight with the following primary 
antibodies diluted in blocking buffer: anti-ataxin 3 (1H9; 1:2000; Chemicon, Temecula, CA, 
USA), anti-ataxin-2 (1:1000; BD Biosciences, San Jose, California, USA), anti-PABP 
(1:2000,Millipore, Temecula, California, USA) and anti-tubulin (1:2000; Sigma, Saint Louis, 
MO, USA).  Blots were washed three times in TBS-T, for 15min each, and incubated with the 
secondary antibody goat anti-mouse (1:10 000; Vector Laboratories, Burlingame, CA) for 2h 
at room temperature. After washing, bands were visualized with Enhanced Chemifluorescent 
substract (ECF) (GE Healthcare, Amersham, UK) and chemifluorescence imaging (Versadoc 
Imaging System Model 3000, Bio-Rad, Munich, Germany. Semi quantitative analysis was 
carried out based on the optical density (OD) of scanned films (Quantity One 1-D image 
analysis software version 4.4; Biorad, Hercules, CA, USA). Specific ODs were normalized with 
respect to those for tubulin for experiments on total homogenates. The specific OD was then 
normalized with respect to the amount of tubulin loaded in the corresponding lane of the 
same gel. A partition ratio was calculated and expressed as a percentage. The western 
blotting analyses were performed in triplicate for each experimental set when possible.
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3.1. Ataxin-2 immunoreactivity is increased in Machado-Joseph 
disease patient brain tissue 
An abnormal connection between ataxin-2 and ataxin-3 was described in a Drosophila 
model, in which ataxin-2 was shown to have a determinant role in MJD pathogenesis (Lessing 
and Bonini, 2008). Moreover, it has also been shown that normal ataxin-2 is present in 
nuclear inclusions of mutant ataxin-3 in MJD patients (Uchihara et al., 2001). Therefore we 
investigated if the levels of ataxin-2 were changed in post-mortem brain tissue of Machado-
Joseph disease patients.  
The immunoreactivity of ataxin-2 in two brain regions affected – the striatum and 
cortex of three autopsy-confirmed Machado-Joseph disease patients was compared to two 
age matched controls. Increased ataxin-2 immunoreactivity was observed in MJD patients 
compared to the controls in striatum (Figure 10B left panel; P<0,001), and cortex (Figure 10B 
right panel; P<0,01). This increase in ataxin-2 levels was more significant in striatum, which 
is an area more affected in MJD as compared with the cortex that is relatively spared 
(Sudarsky and Coutinho, 1995; Coutinho and Andrade, 1995; Alves et al., 2008).  
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Figure 10. Ataxin-2 immunoreactivity is increased in the brain tissue of Machado-Joseph 
disease patients. (A,B) Ataxin-2 immunohistochemistry in striatum and cortex of MJD patient’s brains 
(MJD, n=3), and age-matched controls (Control, n=2). (A) Representative brain sections stained for 
ataxin-2 to highlight ataxin-2 localization in the striatum and cortex of MJD patients and control 
(fluorescence microscopy). (B) Quantitative analysis of ataxin-2 immunoreactivity in the striatum and 
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cortex. The immunohistochemistry was performed in triplicate, analyzed in the same day at same 
exposure. Values are expressed in mean ± SEM. **P<0.01; ***P<0.001 (unpaired Student’s t-test).  
 
3.2. Ataxin-2 and PABP levels are increased in Machado-Joseph 
disease patient fibroblasts 
 To further investigate the interaction between ataxin-2 and ataxin-3 we also studied 
the role of poly-A-binding protein (PABP) (Ralser et al. 2005), as it has been suggested that 
ataxin-2 and ataxin-3 proteins do not interact directly, but rather through PABP (Lim et al. 
2006). Therefore the next step for our investigation was evaluating ataxin-2 and PABP levels 
in the disease (MJD fibroblasts). In order to obtain these results, we performed an 
immunocitochemistry of fibroblasts derived from MJD patients (n=2) and controls (n=1), 
stained for ataxin-2 (red), ataxin-3 (green) (Figure 11A) and PABP (red) (Figure 12A). The 
immunoreactivity was analyzed in several slides and quantified for ataxin-2 (Figure 11B) and 
PABP (Figure 12B).  
In MJD patient’s fibroblasts it was possible to observe the presence of ataxin-2 in the 
nucleus of the cells similarly to ataxin-3, a subcellular pattern that was not present in control 
fibroblasts where both ataxin-2 and ataxin-3 were confined to the cytoplasm (Figure 11A). 
Furthermore, we observed that the immunoreactivity for ataxin-2 was increased in the MJD 
fibroblasts at the cellular level when compared with the control (Figure 11B left panel; 
P<0.001), and in the nucleus where this difference was even more significant (Figure 11B 
right panel; P<0.0001).  
In addition, western blotting analysis of fibroblasts from MJD patients and controls 
fibroblast (Figure 11C) revealed that ataxin-2 levels relative to tubulin were significantly 
increased in MJD patient fibroblasts (Figure 11D) when compared with the controls (Figure 
11D; P <0,01). 
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Figure 11. Ataxin-2 is recruited to the nucleus and upregulated in MJD patients fibroblasts (A,B) 
Immunocytochemical analysis of fibroblasts of MJD patients (MJD, n=2) and fibroblasts of controls 
(Control, n=1) by staining nuclei (DAPI, blue), ataxin-3 (Ataxin-3, green) and ataxin-2 (Ataxin-2, red). 
(A) In MJD, ataxin-2 was recruited to the nucleus, a phenomenon that was not observed in the controls, 
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despite the absence of intranuclear inclusions in MJD patient’s fibroblasts. (B) Immunoreactivity of 
ataxin-2 in the whole cell was increased in MJD, as well as in the nucleus, comparative to controls. 
Immunocitochemistry was performed in triplicate; with two slides per group and at least 12 snaps per 
slide, at the same exposure at the same time.  Values are expressed in mean ± SEM. ***P<0.001; 
****P<0.0001 (unpaired Student’s t-test). (C, D) Western blotting analysis of lysates of human 
fibroblasts derived from MJD patients and from a control individual. (C) Representative western-blot 
probed for endogenous human ataxin-2 (MW: ≅ 148kDa) and tubulin (MW: 55kDa) proteins. (D) 
Optical densitometry analysis reveals an increase in the ataxin-2 levels as compared to the control. 
Each ataxin-2 lane was normalized according to the tubulin band. Results were expressed as ratio 
Ataxin-2/ Tubulin (n=3 for each experimental set). Values are expressed as mean ± SEM. ***P<0.001 
(Student’s t-test). Three replicates of the blots were performed to ensure the reliability of data. 
We then analyzed the levels of PABP in MJD patient’s fibroblasts and controls (Figure 
12). Even though PABP was not found extensively recruited into the nucleus of MJD patient 
fibroblasts (Figure 12A) it is possible to observe differences relatively to the control 
fibroblasts. An increased immunoreactivity for PABP was observed in MJD patient fibroblasts 
as compared to control fibroblasts. Moreover, we detected a significant increased 
immunoreactivity of PABP in the MJD fibroblasts when compared with the controls (Figure 
12B; P<0.001). In addition, western blotting analysis of fibroblasts from MJD patients (Figure 
12C) and control fibroblasts (Figure 12C) confirmed that PABP levels normalized to tubulin 
were increased in MJD patients (Figure 12D) when compared with the controls (Figure 12D; 
P <0,05), as previously observed for ataxin-2 levels. 
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Figure 12. PABP levels are increased in MJD patient’s fibroblasts. (A,B) Immunocytochemical 
analysis of fibroblasts from MJD patients (MJD, n=2) and fibroblasts from control individuals (Control, 
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n=1) with staining for nuclei (DAPI, blue), ataxin-3 (Ataxin-3, green) and PABP (PABP, red). (A) PABP 
staining is slightly increased in the nucleus of fibroblasts from MJD patients as compared to controls. 
(B) Immunoreactivity of PABP was significantly higher in MJD, comparative to controls. 
Immunocitochemistry was performed in triplicate; in two slides per group and at least 12 snaps per 
slide, at the same exposure in the same day. Values are expressed in mean ± SEM. ****P<0.0001 
(unpaired Student’s t-test). (C,D) Western blotting analysis of lysates of fibroblasts derived from MJD 
patients (MJD) and from a control individual. (C) Representative western-blot probed for endogenous 
human PABP (MW: 71kDa) and tubulin (MW: 55kDa) proteins. (D) Optical densitometry analysis. An 
increase in the PABP levels as compared with the control is observed. Each PABP lane was normalized 
according to the tubulin band. Results were expressed as ratio PABP/ Tubulin (n=3 for each 
experimental set). Values are expressed as mean ± SEM. *P<0.05 (Student’s t-test). Three replicates of 
the experiment were performed.  
 
3.3. Ataxin-2 and PABP levels decrease with the progression of 
the disease in a lentiviral-based MJD model 
After accessing data regarding human tissue, we next studied if we would obtain the 
same results in a lentiviral MJD model (Alves et al., 2008). We tried to unravel if it was 
observed altered expressions of ataxin-2 and PABP in mice with MJD, similarly to our results 
in human tissue. For this purpose mice were injected with lentiviral vectors encoding mutant 
ataxin-3 (72Q) in one hemisphere and wild type ataxin-3 (27Q) in the contralateral 
hemisphere, thus acting as an internal control. The immunohistochemistry and quantitative 
analysis for ataxin-2 revealed a significant reduction in the levels of ataxin-2 from 2 weeks 
(n=3, Figure 13A upper lane, Figure 13B) to 4 weeks (n=3, Figure 13A middle lane, Figure 
13B, P<0.01). This reduction of ataxin-2 levels was also confirmed at 8 weeks (n=3, Figure 
13A lower lane, Figure 13B, P<0.05). 
Upon evaluation of the PABP levels in the same model (Figure 14A, B), the results 
were similar as the ones obtained with ataxin-2. Immunohistochemistry and quantitative 
analysis for PABP revealed a significant reduction in its levels from 2 weeks (n=3, Figure 14A 
upper lane, Figure 14B) to 4 weeks (n=3, Figure 14A middle lane, Figure 14B, P<0.01) and 
then to 8 weeks (n=3, Figure 14A lower lane, Figure 14B, P<0.05). 
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Figure 13. Ataxin-2 levels decrease with the progression of MJD in a lentiviral-based model. 
(A,B) Immunohistochemical analysis of mouse sections expressing human wild type and mutant 
ataxin-3 upon lentiviral injection. The analyses were performed at 2 weeks (n=3, upper lane), 4 weeks 
(n=3, middle lane) and 8 weeks (n=3, lower lane) post-injection by staining for the nuclei (DAPI, blue), 
for ataxin-3 (ataxin-3, green) and for ataxin-2 (ataxin-2, red). (A) Representative brain sections stained 
for ataxin-2 (confocal microscopy), it was notable the decrease of ataxin-2 levels with the progression 
of time. (B) The immunoreactivity decreased over time, being the decrease more evident in the interval 
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of 2 to 4 weeks. The immunohistochemical analysis was performed in triplicate, with at least three 
sections per animal, at the same color of staining, analyzed in the same day at same exposure. Values 
expressed in mean ± SEM. *P<0.05, **P<0.01; ***P<0.001 (One-way Anova).  
 
Figure 14. PABP levels decrease with the progression of MJD in a lentiviral model. (A,B) 
Immunohistochemical analysis of rat sections expressing human wild type and mutant ataxin-3 upon 
lentiviral injection. The analyses were performed at 2 weeks (n=3, upper lane), 4 weeks (n=3, middle 
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lane) and 8 weeks (n=3, lower lane) post-injection by staining for the nuclei (DAPI, blue), for ataxin-3 
(ataxin-3, green) and for PABP (PABP, red). (A) Representative brain sections stained for PABP and 
ataxin-3 to highlight PABP levels in the brain sections, it was notable the diminishing of PABP levels 
with the progression in time (confocal microscopy). (B) The immunoreactivity analysis leads to the 
conclusion that PABP levels are significantly decreasing over time, being the decrease more 
accentuated in the interval of 2 to 4 weeks. The immunohistochemmical was performed in triplicate, 
with at least three sections per animal, at the same color of staining, analyzed in the same day at same 
exposure. Values expressed in mean ± SEM. *P<0.05, **P<0.01; ***P<0.001 (One-way Anova). 
 
3.4. Ataxin-2 and PABP levels are altered in a MJD transgenic 
mouse model  
To further investigate how the levels of ataxin-2 and PABP are modified by MJD 
pathogenesis we analyzed a MJD transgenic mouse model (Torashima et al., 2008). For this 
purpose we performed immunohistochemical staining for ataxin-2 and PABP in brain 
sections, and western blotting analysis of cerebellar punches and other brain regions of 
transgenic MJD Q69 mice, using wild-type C57BL6 mice as control. 
Immunohistochemistry of ataxin-2 revealed a reduction in the immunoreactivity for 
ataxin-2 at the level of the Purkinje cell layer in the MJD Q69 compared to WT mice, which 
was confirmed by quantification of fluorescence (n=6, Figure 15A, B, P<0.05).  Nevertheless, 
in western-blot of punches of cerebellum, the opposite was observed: there was a significant 
increase in ataxin-2 levels in the MJD-Q69 punches (n=3, Figure 15C, Figure 15D left panel, 
P<0.001), relatively to the WT punches (n=3, Figure 15C, Figure 15D). 
Additionally, western blot of punches from different brain regions, revealed the 
ataxin-2 expression in different brain areas. It was clear that decreased levels of ataxin-2 
were found in the striatum (Figure 15E) as compared to other brain regions of this mouse 
model using tubulin as reference. 
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Figure 15. Ataxin-2 levels are altered in a MJD transgenic mouse model. (A,B) 
Immunohistochemical analysis of brain sections of MJD-Q69 mice (n=6) and WT C57BL6 (n=6) for 
ataxin-2. (A) Ataxin-2 immunoreactivity was observed in sections of WT mice, mainly in the Purkinje 
cells, and was reduced in the MJD-Q69 mice at this level. (B) Immunoreactivity of ataxin-2 is 
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significantly lower in the MJD Q69 mice, comparative the controls. Immunohistochemical fluorescence 
analysis was performed in triplicate; with at least 3 snaps per section, at the same exposure in the 
same day. Values expressed in mean ± SEM. *P<0.05 (unpaired Student’s t-test). (C, D) Western 
blotting analysis of cerebellar punches of WT C57BL6 (n=3) and MJD Q69 (n=3) mice. (C) 
Representative western-blot probed for endogenous human ataxin-2 (MW: ≅ 148kDa) and tubulin 
(MW: 55kDa) proteins. (D) Optical densitometric analysis reveals an increase in the ataxin-2 levels in 
MDJ-Q69 punches. Each ataxin-2 lane was normalized according to the tubulin band, used as a loading 
control. Results are expressed as ratio ataxin-2/ Tubulin (n=3 for each experimental set). Values are 
expressed as mean ± SEM. **P<0.01; *** P<0.001 (t-test). Three replicates of the protocol were 
performed. (E) Representative western blot of punches of striatum, cortex, hippocampus and 
cerebellum of WT C57BL6 (n=3) and MJD Q69 (n=3) mice, probed for endogenous human ataxin-2 
(MW: ≅ 148kDa) and tubulin (MW: 55kDa) proteins. Decreased levels of ataxin-2 were found in the 
striatum.  
The immunocitochemistry (Figure 16A) and quantitative analysis (Figure16B) for 
PABP revealed that its levels were significantly reduced in the MJD-Q69 brain sections 
(Figure 16A) compared to WT mice at the level of the Purkinje cell layer (n=5, Figure 16B, 
P<0.001). In western-blot of cerebellar punches, it was also observed a decrease in PABP 
levels of the MJD Q69 (n=3, Figure 16C, Figure 16D), relatively to the WT (n=3, Figure 16C, 
Figure 16D), even though this decrease did not prove to be significant. Additionally, western 
blot of different brain regions punches, revealed that levels of PABP are different in those 
areas, with higher density of PABP lane in the cerebellum (Figure 16E) and lower density of 
the striatal lane, as compared to the other regions (Figure 16E).   
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Figure 16.  PABP levels are altered in a MJD transgenic mouse model. (A,B) Immunohistochemical 
analysis of brain sections of MJD-Q69 mice (n=5) and WT C57BL6 (n=5) mice for PABP. (A) PABP 
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immunohistochemical staining was observed in the sections of WT mice, particularly in the Purkinje 
cell layer but was significantly decreased in the MJD Q69 brain sections. (B) Immunoreactivity of PABP 
is significantly lower in the MJD-Q69 mice, compared to the controls. Immunohistochemistry was 
performed in triplicate; with at least 3 snaps per section, at the same exposure in the same day.  Values 
are expressed in mean ± SEM. ***P<0.001 (unpaired Student’s t-test). (C, D) Western blotting analysis 
of cerebellar punches of WT C57BL6 (n=3) and MJD Q69 (n=3) mice. (C) Representative western-blot 
probed for endogenous PABP (MW: 71kDa) and tubulin (MW: 55kDa) proteins. (D) Optical 
densitometric analysis. A non-significant decrease in the PABP levels was observed in MDJ-Q69 
punches.  Each PABP lane was normalized according to the tubulin band used as a loading control. 
Results were expressed as ratio PABP/ Tubulin (n=3 for each experimental set). Values are expressed 
as mean ± SEM. ns.P>0.05 (t-test). Three replicates of the protocol were performed. (E) Representative 
western blot of punches of striatum, cortex, hippocampus and cerebellum of WT C57BL6 (n=3) and 
MJD Q69 (n=3) mice, probed for endogenous PABP (MW: 71kDa) and tubulin (MW: 55kDa) proteins.  
 
3.5. Ataxin-2 and PABP levels are altered in a cellular model of 
Machado-Joseph disease 
 After accessing data from the human tissue, lentiviral and transgenic MJD models, we 
developed a cellular MJD model in order to further investigate the changes in ataxin-2 and 
PABP expression levels associated to the disorder. Neuro-2a cells (obtained from the ATCC 
cell biology bank (CCL-131)) were infected with lentiviral vectors encoding human normal 
length ataxin-3 (27Q) and human mutant expanded ataxin-3 (72Q). 
 Western blot analysis suggests that the levels of ataxin-2 were decreased in cells 
expressing mutant ataxin-3 (n=3, ATX3 MUT, Figure 17A) relatively to controls. 
Densitometric quantification using tubulin as loading control confirmed that the levels of 
ataxin-2 were significantly diminished in cells expressing mutant ataxin-3 (Figure 17B), 
relatively to the non-infected cells (Figure 17B, P<0.01), and also significantly reduced when 
compared with the cells expressing wild type ataxin-3 (Figure 17B, P<0.001). These data 
suggest that in the cellular model of MJD, levels of ataxin-2 are reduced similarly to the 
results found in the lentiviral MJD mouse model in which ataxin-2 tends to decrease with the 
progression of the disease.  
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Figure 17. Ataxin-2 levels are decreased in a MJD cellular model. (A,B) Western blotting analysis 
of non-infected (NI, n=3), expressing human wild-type ataxin-3 (Atx3WT, n=3) and human expanded 
ataxin-3 (Atx3MUT, n=3) cell lysates. (A) Representative western-blot probed for ataxin-2, ataxin-3 
and tubulin. Note the presence of endogenous ataxin-2 (MW: ≅ 148kDa), human Atx3 WT/ATx3-27Q 
(MW: 50kDa), Atx3Mut/Atx3-72Q (MW: 67kDa) and tubulin (MW: 55kDa). (B) Optical densitometry 
analysis. Significant decrease in the levels of ataxin-2 was observed in the cells expressing Atx3MUT 
relatively to the NI cells and the Atx3WT expressing cells. Each ataxin-2 lane was normalized according 
to the tubulin band. Tubulin was used as a loading control. Results were expressed as ratio Ataxin-2/ 
tubulin (n=3 for each experimental set). Values are expressed as mean ± SEM. **P<0.01; ***P<0.001 
(One-Way Anova test). Three replicates of the protocol were performed. 
Regarding the levels of PABP in this MJD cellular model, an increase in PABP levels 
was observed in cells expressing wild-type ataxin-3 (n=3, Atx3WT, Figure 18A, Figure 18B) 
when compared with non-infected cells (n=3, NI, Figure 18A, Figure 18B, P<0.01). The same 
Interaction of ataxin-2 and ataxin-3 in Machado Joseph disease - Results 
 
Page | 63  
 
increase was observed in cells expressing mutant ataxin-3 (n=3, Atx3MUT, Figure 18A, Figure 
18B, P<0.05) compared with non-infected cells. No significant differences were detected 
between Atx3WT and Atx3MUT cells.  
 
Figure 18. PABP levels are increased in a MJD cellular model. (A, B) Western blotting analysis of 
neuro2A cells: non-infected (NI, n=3), expressing human wild-type ataxin-3 (Atx3WT, n=3) and 
expressing human expanded ataxin-3 (Atx3MUT, n=3) cell lysates. (A) Representative western-blot 
probed for PABP, ataxin-3 and tubulin. Note the presence of endogenous PABP (MW: 71kDa), human 
Atx3 WT/ATx3-27Q (MW: 50kDa), Atx3Mut/Atx3-72Q (MW: 67kDa) and tubulin (MW: 55kDa). (B) 
Optical densitometry analysis. A significant increase in the levels of PABP was observed in cells 
expressing Atx3WT and in those expressing Atx3MUT relatively to the NI cells. Each PABP lane was 
normalized according to the tubulin band. Tubulin was used as a loading control. Results were 
Interaction of ataxin-2 and ataxin-3 in Machado Joseph disease - Results 
 
Page | 64  
 
expressed as ratio PABP/ Tubulin (n=3 for each experimental set). Values are expressed as mean ± 
SEM. *P<0.05; **P<0.01 (One-Way Anova test). It was performed three replicates of the protocol. 
 
3.6. Overexpression of ataxin-2 and PABP reduce ataxin-3 
levels in a neuro2a MJD model 
 We further analyzed ataxin-3, ataxin-2, and PABP network connection, by co-infecting 
N2a cells with lentiviral vectors encoding Atx3WT or Atx3MUT and Ataxin-2 or PABP, to 
access the effect of these co-infections not only in the levels of ataxin-3, but also in ataxin-2 
and PABP levels.  
 Upon infection of cells expressing Atx3WT and Atx3MUT with ataxin-2-encoding 
vectors we performed western-blotting of cell lysates (Figure 19A). The membranes were 
probed for ataxin-2, PABP, ataxin-3 and tubulin in order to access the levels of the different 
proteins upon co-infection (Figure 19A). We found that the levels of ataxin-3 (relative to 
tubulin) in Atx3WT cells infected with ataxin-2 (Atx2) (Atx3Wt+Atx2, n=3) were significantly 
decreased (Figure 19B upper panel, P<0.01) relatively to the Atx3WT cells non-infected with 
Atx2 (Atx3WT, n=3). A similar effect was observed in Atx3MUT cells co-infected with vectors 
encoding ATX2 (Atx3MUT+Atx2, n=3), with an even more significant decrease (Figure 19B 
upper panel, P<0.001) compared to the Atx3-MUT cells non-infected with Atx2 (Atx3MUT, 
n=3). Densitometric analysis confirmed a significant decrease of wild-type (Figure 19B lower 
panel, P<0.001) and mutant ataxin-3 (Atx3MUT cells; Figure 19B lower panel, P<0.001) levels 
upon ataxin-2 co-expression. 
 Analysis of PABP levels (relative to tubulin) also yielded significant results. An 
increase (Figure 19C, P<0.05) of PABP levels in the Atx3WT+Atx2 cells when compared to the 
non-infected, Atx3WT cells was detected. This increase was also observed in the 
Atx3MUT+Atx2 cells, even though much more accentuated (Figure 19C, P<0.001). 
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Figure 19. Ataxin-2 overexpression mediates decrease of ataxin-3 and increase of PABP levels. 
(A-C) Western blotting analysis of: non-infected (NI, n=3), expressing human wild-type ataxin-3 
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(Atx3WT, n=3), expressing human wild-type ataxin 3 infected with ataxin 2 (Atx3WT+Atx2, n=3), 
expressing human expanded ataxin-3 (Atx3MUT, n=3), expressing human expanded ataxin-3 infected 
with ataxin-2 (Atx3MUT+Atx2, n=3) cells. (A) Representative western-blot probed for Ataxin-2, PABP, 
ataxin-3 and tubulin. Note the presence of endogenous Ataxin-2 (MW: ≅ 148kDa), PABP (MW: 71kDa), 
human Atx3 WT/ATx3-27Q (MW: 50kDa), Atx3Mut/Atx3-72Q (MW: 67kDa) and tubulin (MW: 
55kDa). (B) Optical densitometry analysis. Significant decrease in the ataxin-3 levels was observed 
(relative to tubulin and to ataxin-2) in Atx3WT+Atx2 cells relatively to the Atx3WT cells. A similar 
occurrence was observed in the levels of ataxin-3 with Atx3MUT+Atx2 relatively to non-infected 
Atx3MUT cells. The ataxin-3 levels were normalized according to the amount loaded (tubulin band). 
Results are expressed as ratio ataxin-3/tubulin and ataxin-3/ataxin-2 (n=3 for each experimental set). 
Values are expressed as mean ± SEM. **P<0.01; ***P<0.001 (Student’s t-test). Three replicates of the 
protocol were performed. (C) Optical densitometry analysis. Significant increase in PABP levels was 
detected (relative to tubulin) in Atx3WT+Atx2 cells relatively to the Atx2WT cells. A similar 
occurrence was observed in the levels of PABP in Atx3MUT+Atx2 relatively to Atx3MUt cells. Each 
PABP lane was normalized according to the tubulin band. Tubulin was used as a loading control. 
Results were expressed as ratio PABP/ Tubulin (n=3 for each experimental set). Values are expressed 
as mean ± SEM. *P<0.05; ***P<0.001 (Student’s t-test). 
A similar experience was conducted by infecting cells expressing Atx3WT and 
Atx3MUT with lentiviral vectors encoding for PABP and performing western-blotting of the 
cell lysates (Figure 20A). The membranes were probed for ataxin-2, PABP, ataxin-3 and 
tubulin in order to access different expressions due to the co-infection (Figure 19A). The 
levels of ataxin-3 (relative to tubulin) in Atx3WT cells infected with PABP (Atx3Wt+PABP, 
n=3) were significantly decreased (Figure 20B upper panel, P<0.001) relatively to the 
Atx3WT cell non-infected (Atx3WT, n=3). The same occurred in the levels of ataxin-3 in 
Atx3MUT cells infected with PABP (Atx3MUT+PABP, n=3), with a significant decrease (Figure 
20B upper panel, P<0.01) compared to the Atx3-MUT cells non-infected with PABP 
(Atx3MUT, n=3). Analyzing the results of ataxin-3 levels relative to PABP levels, the results 
were very similar; a significant decrease of ataxin-3 levels was observed in Atx3WT+PABP 
cells compared to Atx3WT cells (Figure 20B lower panel, P<0.01). A similar decrease was 
observed in Atx3MUT+PABP relatively to Atx3MUT cells (Figure 20B lower panel, P<0.001).  
 Analysis of ataxin-2 levels (relative to tubulin) did not show significant differences in 
the ataxin-2 levels between Atx3WT+PABP and Atx3WT (Figure 20C, P>0.05). However, in 
Atx3MUT+PABP cells a significant increase of ataxin-2 levels was observed relatively to 
Atx3MUT cells (Figure 20C, P<0.001).  
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Figure 20. PABP overexpression decreases the levels of ataxin-3 expression and increases the 
levels of ataxin-2 expression. (A-C) Western blotting analysis of non-infected cells (NI, n=3), or cells 
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infected with lentiviral vectors encoding, respectively: human wild-type ataxin-3 (Atx3WT, n=3), 
human wild-type ataxin 3 and PABP (Atx3WT+PABP, n=3), human expanded ataxin-3 (Atx3MUT, n=3), 
human expanded ataxin-3 and PABP (Atx3MUT+PABP, n=3) cells. (A) Representative western-blot 
probed for ataxin-2, PABP, ataxin-3 and tubulin. Note the presence of endogenous ataxin-2 (MW: ≅ 
148kDa), PABP (MW: 71kDa), human Atx3 WT/ATx3-27Q (MW: 50kDa), Atx3Mut/Atx3-72Q (MW: 
67kDa) and tubulin (MW: 55kDa). (B) Optical densitometry analysis. Significant decrease in ataxin-3 
levels (relative to tubulin and to PABP) was observed in Atx3WT+PABP cells relatively to the Atx3WT 
cells. Similarly, the levels of ataxin-3 decreased with Atx3MUT+PABP relatively to non-infected 
Atx3MUt cells. Ataxin-3 levels were normalized according to the amount loaded (tubulin band). Results 
are expressed as ratio ataxin-3/tubulin and ataxin-3/PABP (n=3 for each experimental set). Values are 
expressed as mean ± SEM. **P<0.01; ***P<0.001 (Student’s t-test). Three replicates of the protocol 
were performed. (C) Optical densitometry analysis. Note that there were no significant differences in 
Atx3WT+PABP and Atx3WT cells. Significant increase in ataxin-2 levels (relative to tubulin) in 
Atx3MUT+Atx2 relatively Atx3MUT cells. Each Ataxin-2 lane was normalized according to the tubulin 
band. Tubulin was used as a loading control. Results were expressed as ratio PABP/ Tubulin (n=3 for 
each experimental set). Values are expressed as mean ± SEM. ns;  P>0.05; ***P<0.001 (Student’s t-test).  
 
3.7. Silencing PABP does not alter ataxin-3 neither ataxin-2 
levels but increases mutant ataxin-3 aggregates 
 To further investigate the dynamics of the ataxin-3, ataxin-2 and PABP network we 
performed silencing of PABP. Evidence from the previous section suggested that 
overexpression of PABP could decrease ataxin-3 levels and increase ataxin-2 levels therefore 
we investigated if knocking-down PABP would mediate symmetric effects. 
 For our experiments we used a short-hairpin control (shLuc) and a mix of four short 
hairpin RNA silencing sequences targeting PABP (shPABP), which was used to transfect 
mutant Neuro-2a cells already expressing human mutant ataxin-3. The cells lysates were 
collected 48h after the transfection for western blotting analysis (Figure 21A). The 
membranes were probed for ataxin-2, PABP, ataxin-3 and tubulin in order to access their 
expression levels (Figure 21A). A decrease in the levels of PABP (relative to tubulin) was 
observed in the cells transfected with shPABP (n=3, P<0.01; Figure 21B) relatively the control 
cells (shLuc, n=3; Figure 21B). Nevertheless, there were no significant differences in ataxin-2 
(Figure 21C) and ataxin-3 levels (Figure 21D) (related to tubulin) between the control cells 
and the silenced cells. This may result from the low knocking-down that was obtained with 
the shRNAs.  However, a small but significant increase in the aggregate levels of mutant 
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ataxin-3 (found in upper portion of the blot corresponding to the stacking gel) was observed 
in the PABP silenced cells when compared to the control cells (Figure 21E, P<0.01). Further 
experiments with more efficient silencing sequences are necessary to confirm these results. 
 
Figure 20. PABP silencing increases aggregate formation. (A-E) Cell lysates western blotting 
analysis of Atx3MUT cells transfected with shLuc (controls) (n=3) and transfected with shPABP (n=3).  
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(A) Representative western-blot probed for Ataxin-2, PABP, ataxin-3 and tubulin. Note the presence of 
endogenous ataxin-2 (MW: ≅ 148kDa), PABP (MW: 71kDa), ataxin-3 aggregates (MW> 250kDa), 
Atx3Mut/Atx3-72Q (MW: 67kDa) and tubulin (MW: 55kDa). (B) Optical densitometry analysis. It was 
possible to observe a decrease in the levels of PABP (relative to tubulin) in the cells transfected with 
shPABP relatively the control cells (shLuc), as expected. The PABP levels were normalized according to 
the amount loaded (tubulin band). Results were expressed as ratio PABP/tubulin (n=3 for each 
experimental set). Values are expressed as mean ± SEM. **P<0.01; **P<0.01 (Student’s t-test). (C) 
Optical densitometry analysis. There were no significant differences in ataxin-2 between the control 
cells and the silenced cells. The ataxin-2 levels were normalized according to the amount loaded 
(tubulin band). Results were expressed as ratio ataxin-2/tubulin (n=3 for each experimental set). 
Values are expressed as mean ± SEM. ns.P>0.05 (Student’s t-test). (D) Optical densitometry analysis. 
There were no significant differences in ataxin-3 between the control cells and the silenced cells. The 
ataxin-3 levels were normalized according to the amount loaded (tubulin band). Results were 
expressed as ratio ataxin-3/tubulin (n=3 for each experimental set). Values are expressed as mean ± 
SEM. ns.P>0.05 (Student’s t-test). (E) Optical densitometry analysis. It was verified an increase in the 
aggregates of mutant ataxin-3 (found in the stacking) in the silenced cells when compared to the 
control cells. The aggregates levels were normalized according to the amount loaded (tubulin band). 
Results were expressed as ratio aggregates/tubulin (n=3 for each experimental set). Values are 
expressed as mean ± SEM. **P<0.01 (Student’s t-test). 
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4. Discussion 
 In this study we provide evidence of an established interacting network between the 
causative protein of MJD, ataxin-3, its known interactor, ataxin-2 (Lim et al., 2006; Lessing and 
Bonini, 2008), and the only PABC containing protein that interacts with ataxin-2, PABP 
(Kozlov et al., 2001). This interactive network was already proven to exist in previous 
research (Lessing and Bonini, 2008), were it was found a toxic effect of ataxin-2 and a 
protective effect of PABP in the MJD phenotype. However, we obtained new evidence 
concerning these three proteins interactions and how affecting expression of one of them 
reflects in the others.  
In the first part of this study, it was shown that ataxin-2 and PABP levels are altered in 
Machado-Joseph disease patients. In post-mortem human brain tissue of MJD patients, it was 
found higher levels of ataxin-2 in striatum and cortex, compared to the normal controls. This 
increase in the expression of ataxin-2 was higher in the striatum, a more affected region in 
MJD when compared to the cortex, which is relatively spared (Sudarsky and Coutinho, 1995; 
Coutinho and Andrade, 1995; Alves et al., 2008). These results are concordant to a possible 
neurodegenerative role of ataxin-2, already proven in other neurodegenerative diseases such 
as SCA1 (Fernández-Funez et al., 2000; Al Rahami et al., 2007) and ALS (Elden et al., 2010; Chen 
et al., 2011). In MJD it was previously found an association between the CAG repeat length at 
the SCA2 gene and the severity of fasciculations in MJD phenotype (Jardim et al., 2003). More 
data (Uchichara et al., 2001) fortified this possible role with the finding of non-expanded 
ataxin-2 in MJD intranuclear inclusions. Ataxin-2 incorporation in NIIs, even with 
pathological expansion of the polyQ tract in SCA2, was considered limited (Huynh et al., 1999; 
Koyano et al., 1999; Koyano et al., 2000), therefore its incorporation in MJD may suggest a real 
and active role in the disease pathogenesis for ataxin-2. Moreover, in fibroblasts from MJD 
patients, we also found an increase in ataxin-2 and PABP levels; also consonant with data 
from brain. Levels of ataxin-2 in the nucleus were found to be much higher than cytoplasmic 
levels in the patients. It was verified a recruitment of ataxin-2 to the nucleus, the possibility of 
an ataxin-2 shuttling may explain these observations. If contrarily to what is currently though 
(Huynh et al., 1999; Uchichara et al., 2001), ataxin-2 is able to acquire some type of shuttling 
capacity, it may explain why protein levels are also elevated in the cytoplasm, even while 
being recruited to the nucleus. Alternatively, ataxin-2 in the cytoplasm, its normal 
localization, may be required for the development of certain cellular responses, which may 
involve ataxin-2’s metabolization or processes which impair the recognition of its epitopes, 
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leading to an inaccurate reading. Several studies were conducted regarding the subcellular 
localization of ataxin-2, however is still not clarified; it is currently a controversial matter 
whether if it is a cytoplasmic or nuclear protein (Huynh et al., 1999; Lastres-Becker et al., 
2008), but evidence point it to be an almost exclusively cytoplasmic protein. It is known 
however, that in SCA2, mutant ataxin-2 accumulates both in the cytoplasm and in the nucleus, 
even though differently. The presence of pathogenic expansions does not lead to intranuclear 
inclusions contrarily to other polyglutamine diseases, but rather produces stranger and more 
diffuse cytoplasmic signals; in addition its nuclear localization it’s not required to induce 
toxicity (Huynh et al., 1999). However the recruitment of ataxin-2 has already been reported 
in SCA1 (Al Rahami et al., 2007), where ataxin-2 located in the nucleus was verified much 
more harmful than in the cytoplasm once it interferes with the transcriptional machinery and 
becomes a potent pathogenesis mechanism (Al Rahami et al., 2007). It seems that mutant 
ataxin-2 with expanded polyQ tract does not increases the toxicity in SCA2 if translocated 
into the nucleus, however wild type ataxin-2 gains a destructive function once recruited into 
the nucleus in other polyQ diseases (such as ataxin-1).  PABP levels were also increased in the 
MJD patients, although the evidences point to partial localization in the nucleus, its 
recruitment is not as obvious as the observed for ataxin-2. PABP is a RNA-binding protein 
which associates with the 3’-poly(A) tail of eukaryotic mRNA (Amrani et al., 1997), it is a 
multifunctional protein involved in many different cellular functions, including translation, 
mRNA metabolism, and mRNA export (Afonina et al., 1998; Brune et al., 2005). It is known its 
nucleoshuttling capacity; it can be present in the nucleus or in the cytoplasm depending on its 
functions (Afonina et al., 1998; Brune et al., 2005).  In our results, we found some PABP in the 
nucleus; however this may not result from direct recruitment due to the pathology. Data 
found leaves us the doubt whether PABP is located in the nucleus or not in MJD. If in the 
control fibroblast it is not verified PABP in the nucleus, but in MJD patient fibroblast there are 
evidence of a certain nuclear localization. If indeed the recruitment of PABP into the nucleus 
in MJD is occurring, may concern PABP’s functions requiring its nuclear localization. On the 
other hand, PABP in the nucleus may be compromising transcriptional processes since its 
localization in the cytoplasm is required for those functions, which can be damaging for the 
cell and lead to the worsening of the pathology. 
A previous work (Lessing and Bonini, 2008) related ataxin-2’s toxicity to its PAM2 
motif. The PAM2 motif binds specifically to the PABC domain, and PABP is currently the only 
known protein containing a PABC domain able to interact with ataxin-2 (Kozlov et al., 2001). 
Using an ataxin-2 lacking the PAM2 motif, it was verified an accelerated inclusion formation 
Interaction of ataxin-2 and ataxin-3 in Machado Joseph disease - Discussion 
 
Page | 74  
 
(Lessing and Bonini, 2008); since the PAM2 motif is required for the connection of PABP it is 
safe to say that the impossibility of PABP connection to ataxin-2 leads to an exacerbation of 
the pathology. Therefore, these results could point to a regulatory activity towards ataxin-2, 
what could account for the elevation of PABP levels to annul some of the toxic activity of 
ataxin-2 in MJD but also a possible protective role of PABP in MJD by connecting to ataxin-2 
and preventing its toxic effect.  
In the attempt to better understand the correlation between the levels of ataxin-3, 
ataxin-2 and PABP, we continued our study by accessing levels of ataxin-2 and PABP in MJD 
models.  
In the lentiviral MJD model (Alves et al., 2008) we further obtained data and evidence 
of ataxin-2 and PABP in the progression of the disease. With disease progression, and the 
increase in the number of intranuclear inclusions of mutant ataxin-3, the levels of ataxin-2 
and PABP were drastically reduced when compared to an earlier state. These results were 
opposite to the increase of their levels observed in MJD patients. In this model like in patients 
there is an ataxin-2 recruitment in to the nucleus, which can lead to its depletion in the 
cytoplasm in a more advanced stage of the disease. This cytoplasmic depletion and ataxin-2’s 
nuclear accumulation are consistent with the neuropathology aggravation with the 
progression of the disease. However, in this lentiviral MJD model, the ataxin-3 provided is 
human, due to the inter-species discrepancy it is possible that it doesn’t exist compensatory 
mechanisms to restore ataxin-2 levels in the cytoplasm, therefore its depletion over time. 
PABP, as referred, is a protein with shuttling capacity accordingly to its functions (Afonina et 
al., 1998; Brune et al., 2005); it is possible that the advance of the pathology and the decline of 
cellular functions create the necessity of elevated PABP levels in the nucleus, which can also 
lead to its depletion in the cytoplasm. The possible regulatory effect in ataxin-2’s levels may 
also account for its nuclear shuttling, if ataxin-2 is being recruited to the nucleus, then PABP 
can’t regulate its levels in the cytoplasm, therefore shuttling in to the nucleus. However, this 
shuttling may have drastic consequences to the cell integrity; since PABP is essential in 
transcriptional processes (Amrani et al., 1997; Afonina et al., 1998; Mangus et al., 2003; Brune 
et al., 2005) and for those purposes its cytoplasmic localization is required, the cytoplasmic 
depletion of PABP over time may cause irreparable damages to the cell, leading to the 
enhancement of neurodegeneration.  
In a MJD transgenic mice model (Torashima et al. 2008) we observed a decrease of 
ataxin-2 and PABP levels in the cerebellum (by immunoreactivity) compared with normal 
wild-type mice. In MJD patients, the cerebellum is one of the most attained regions 
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(Rosenberg, 1992; Sudarsky and Coutinho, 1995; Durr et al., 1996; Rub et al., 2006., Alves et al., 
2008), and this model has a predominantly expression of mutant Ataxin-3 in Purkinje cells. 
Ataxin-2 has a widespread expression in the brain but its major localization is seen in the 
Purkinje cells (Nechiporuk et al., 1998; Huynh et al., 1999) Thus, a depletion and degeneration 
of these cells, results in a reduction of the ataxin-2 and PABP levels. However, total protein 
levels of ataxin-2 are increased in the MJD Q69 cerebellum comparatively to the WT mice. 
Regarding the total PABP protein levels was verified a decrease in MJD Q69 mice when 
compared to the WT mice, although this decrease can’t be considered significant. This 
decrease may be a result from PABP metabolization or its epitopes may be hidden or harder 
to access if PABP is localized in the nucleus performing its normal function or enhancing the 
pathology as referred. These results are similar to the human tissue analysis, where we found 
an increase in ataxin-2 levels in MJD patients; in human tissue analysis we also found an 
increase in PABP levels, but as explained, the non-significant decrease observed in the MJD 69 
mice may not correspond to the real scenario.  
In order to better understand how the ataxin-3-ataxin-2-PABP could interact and to 
gather further evidence of ataxin-2 and PABP role in MJD, we looked for the effect of 
expression of one protein in the levels of expressions of the others, in a cellular model. The 
infection of N2a cells with mutant ataxin-3 diminished ataxin-2 levels and increased PABP 
levels. However, ataxin-2’s decrease may be due to its recruitment to the nucleus where once 
incorporated in the aggregates may be difficult to detect. Also, wild type ataxin-3 has an 
important neuroprotective role, depending on a fully functioning proteasome (Warrick et al., 
2005), it’s possible that the endogenous wild type ataxin-3 may be fulfilling its normal 
function and activating clearance mechanisms, leading to the destruction of the aggregates 
(induced by the infection of human expanded ataxin-3) that contain ataxin-2 (Uchihara et al., 
2001), therefore causing a decrease in endogenous ataxin-2 levels. This outcome is probable 
since infection with wild type ataxin-3 didn’t altered ataxin-2’s levels when compared to the 
non-infected cells; highlighting that in normal and non-pathological conditions, ataxin-3 does 
not alter ataxin-2 levels, indicating that this phenomenon may be a protective cellular 
mechanism verified in the disease. Levels of PABP were found to be increased upon infection 
of both ataxin-3 wild type and mutant. These results could point to an interaction between 
PABP and ataxin-3 (normal and mutant), or at least to sub-effect in PABP levels due to the 
expression of ataxin-3. However, contrarily to ataxin-2, this interaction doesn’t seem to be 
verified only in pathological conditions.  
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Once established the effects of ataxin-3 infection in ataxin-2 and PABP’s levels, we 
tried to access the possible effect of ataxin-2 and PABP overexpression in ataxin-3 levels. To 
date, there was only the evidence that ataxin-2 overexpression exacerbated 
neurodegeneration in a MJD model in Drosophila eye. On the contrary, PABP overexpression 
suppressed neurodegenerative phenomenons (Lessing and Bonini, 2008). When co-
expressing human ataxin-2 with human mutant ataxin-3 in N2a cells, the levels of ataxin-3 
were drastically diminished, while levels of PABP increased, which could support PABP 
possible regulatory effect facing the overexpression of ataxin-2. Since ataxin-2’s levels are 
increased there is an increase in PABP levels in order to annul the ataxin-2 possible toxic 
effect. Moreover the co-expression of wild-type ataxin-3 and ataxin-2 also decreased ataxin-3 
levels, which further support a possible interaction between ataxin-2 and ataxin-3. It’s known 
that ataxin-2 has a role in RNA metabolism, regulating translational processes, and that 
modifications in ataxin-2 levels are able to alter the abundance of some proteins (Ciosk et al., 
2004; Satterfield and Pallanck, 2006). In some way still not understood it appears that by 
translational regulation ataxin-2 is able to decrease ataxin-3 levels in a pathological situation 
as MJD.  
The overexpression of PABP also led to a decrease in the overall ataxin-3 levels. Co-
expression of human PABP and human mutant ataxin-3 led to a significant decrease in ataxin-
3 levels, and also in ataxin-2 levels. The same decrease in ataxin-3 levels was observed in the 
co-infection of PABP and wild-type ataxin-3, however, levels of ataxin-2 remained the same, 
did not suffer any alteration when compared to the cells infected only with wild-type ataxin-
3. These results may reflect this correlation between these three proteins, in normal 
conditions (co-infection of wild-type ataxin-3 and PABP), ataxin-2 levels are not altered by 
PABP, but in pathological conditions (co-infection of mutant ataxin-3 and PABP), 
overexpression of PABP leads to an increase in ataxin-2 levels. The possible regulatory role of 
PABP regarding ataxin-2 may therefore be reciprocal and it seems to occur in pathological 
conditions; high levels of ataxin-2 are accompanied by the elevation in PABP levels and vice-
versa, implying some kind of feedback and balance between these two proteins. The results 
point to this interaction as a protective cellular mechanism.  
All together these results points to a synergicall relation between ataxin-2 and PABP, 
which can actively decrease ataxin-3 levels, both in normal and pathological conditions.  
We also tried silencing PABP in order to decipher better its role in the disease, and 
our results corroborate all of our previous findings. Silencing PABP did not altered levels of 
ataxin-3 neither of ataxin-2, which in light to our previous findings shouldn’t have happened; 
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unless the possible feedback mechanism existing between ataxin-2 and PABP also involves 
ataxin-3. If this were the case, silencing PABP would trigger the feedback and ataxin-2 and 
ataxin-3 may not respond by altering significantly their levels in the attempt to cope with the 
decrease in PABP levels. What we found was a significant increase in aggregate formation; 
reinforcing the possibility of a protective role of PABP, that once silenced would not connect 
to the PAM2 motif of ataxin-2, leaving room for ataxin-2’s toxicity. Although these results 
might be explained, the efficiency of the silencing was not ideal, since levels of PABP didn’t 
decreased how it was expected. Levels of PABP should have lowered around 50%, which did 
not occurred and so doesn’t allow us to take more appropriated and accurate insights about 
the effect of PABP silencing in ataxin-2 and ataxin-3 levels. The silencing was performed by 
lipofectamine transfection of shPABP, in order to obtain a more efficient silencing we should 
have used lentiviral vectors encoding shPABP.  
Although the PABP silencing didn’t work entirely it was still possible to observe 
significant differences in the aggregate formation. It is described that PABP connection to 
ataxin-2’s PAM2 motif can suppress its toxicity (Lessing and Bonini, 2008), in the absence of 
PABP it wasn’t verified a decrease in ataxin-3 as observed in infection with ataxin-2. These 
results may indicate that the decrease in ataxin-3 levels observed with mutant ataxin-3 and 
ataxin-2 co-infection, might derivate from a PABP action, since ataxin-2’s overexpression 
clearly induces PABP expression and PABP is able to decrease ataxin-3 levels. This synergy 
between the levels of ataxin-2 and PABP results in a protective condition.  
In our work we collected evidence for a strong and significant correlation between 
ataxin-3, ataxin-2 and PABP. Ataxin-2 might play a role in amplifying toxicity in MJD similarly 
to other neurodegenerative diseases; however, PABP might play the opposite role, protecting 
cells from ataxin-2 induced toxicity and alleviating neurodegeneration. Once all the pending 
questions that remain are answered, then perhaps dampening ataxin-2 toxicity by 
stimulating PABP activity could lead to a MJD treatment. 
 
  
 
 
 
 
 
 
Chapter V 
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5. Conclusion 
In our work, we tried to unravel more about the proteic interaction that seem to 
determine some of MJD’s characteristics. As referred earlier, the CAG repeats don’t account 
for all the variability observed in the disease; therefore understanding the factors that can 
interfere with the age of onset and some phenotypic aspects of MJD may be a stepping stone 
for a new and unexplored field in therapeutics. It’s possible that some these situations may be 
due to proteic network interactions that may somehow lead to an earlier age of onset or even 
certain polymorphisms still not discovered.  
We followed evidences regarding the intriguing proteic interaction between MJD’s 
causative protein Ataxin-3, Ataxin-2 and PABP. We found that in fact there is a network 
interaction which can be determinant for the progression of the disease. It is clear that 
ataxin-2 and PABP expressions are co-dependent, probably by feedback mechanisms, and 
that ataxin-3 becomes a part of this interaction in pathological conditions, such as in MJD. 
Ataxin-2 levels seem to be regulated by PABP, in its turn; PABP plays a neuroprotective role 
protecting the cell from ataxin-2 induced toxicity. Ataxin-2 and PABP appear to create a 
balance in which they are able to diminish Ataxin-3 levels. High levels of ataxin-2 are present 
in the disease and its recruitment to the nucleus involves this protein in MJD’s pathogenesis 
mechanisms; it’s still not understood how this interactive connection functions and what 
triggers PABP’s regulatory functions over ataxin-2. If we could be able to understand why this 
protective effect doesn’t always work and why in certain stage of MJD it becomes impaired 
leading to the exacerbation of neurodegeneration maybe with ataxin-2’s influence; it would 
be possible to find new strategic therapeutics to suppress or delay the MJD’s fatal outcome. 
For this matter it is relevant and possibly determinant to further invest in the study of this 
proteic interactive network.   
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